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1. Introduction 
The tumor can be considered a complex organ where transformed cells characterized by 
high genomic instability and altered gene expression are interconnected and communicate 
with the surrounding microenvironment. The microenvironment (Fig. 1) is composed of a 
large variety of stromal cells including inflammatory, stem and progenitor cells, fibroblasts, 
myofibroblasts, perycites, endothelial and mural cells of the blood vessels which are 
interconnected with the components of the extracellular matrix (ECM). The crosstalk 
between these components and cancer cells deeply affects their survival and proliferation. 
Due to the critical role of these interactions in cancer progression, each cellular or molecular 
component represents a potential target for the development of useful drugs in cancer 
treatment. The cells of the microenvironment are more genetically stable compared to the 
 
 
Fig. 1. Schematic representation of the tumor microenvironment; CAF: Cancer Associated 
Fibroblasts; ECM: extracellular matrix. 
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tumor cells, and a combinatorial treatment targeting both cancer cells and components of 
the microenvironment holds the potential for a more successful outcome. In this chapter will 
list some examples of molecular cues from tumor cells and the surrounding 
microenvironment that are important for tumor growth and progression and due to their 
key role in this process are targets for therapeutic drugs under investigation or in clinical 
use. We will focus on tumor cells and the regulation of proliferation and survival by 
receptor tyrosine kinases and apoptosis. A number of cellular components of the tumor 
microenvironment involved in the process of angiogenesis and how ECM affects this 
process will be taken into account and the effects of some ECM molecules directly affecting 
tumor cell survival and growth will be also discussed.  
1.1 Cell signaling: Receptor tyrosine kinases 
Networks of protein-protein and protein-metabolite interactions are commonly found in 
biological systems where signals must be passed from one location or component within the 
microenvironment to another. Receptor tyrosine kinases (RTKs) have the critical function of 
transducing signals derived from extracellular ligands to several intracellular pathways. 
Regulation of such networks is often achieved by transient, reversible modifications of the 
components involved. To date, more than 200 different types of post translational 
modifications (PTMs) have been identified, but by far the best appreciated and among the 
most important involve phosphorylation of serine, threonine and tyrosine residues. 
Phosphorylation is one of the most studied PTM because it is vital for a large number of 
protein functions and characterizes many cellular processes spanning from signal 
transduction, cell differentiation and development to cell cycle control and metabolism. A 
primary role of phosphorylation is to act as a switch to turn "on" or "off" a protein activity or 
a cellular pathway in an acute and reversible manner (Hunter, 1995). 
Each RTK is composed of an extracellular N-terminal segment able to bind a specific 
extracellular ligand, a transmembrane domain and an intracellular C-terminal segment 
containing the enzymatic domain and a series of tyrosin phosphorylation sites. After ligand 
binding, the dimerization of the receptor induces a trans-phosphorylation of the intracellular 
domain followed by the activation of the catalytic subunit and the transduction of the signal at 
intracellular level. The intracellular domain phosphotyrosines are recognized by downstream 
signal proteins, generally through Src homology-2 (SH2) or phosphotyrosine-binding (PTB) 
domains and their binding induces the activation of the intracellular signaling cascade 
(Hubbard & Miller, 2007). The two main pathways through which RTKs act are the MAPK 
pathway and the PI3K-AKT, although other pathways can be activated under specific 
situations. After receptor dimerization an adaptor protein allows its coupling with a G protein 
that in turn activates a series of intracellular kinases. One of the most studied G proteins is 
called Ras. Mutations that constitutively activate this protein and induce an aberrant 
stimulation of the pathway are often observed in several types of cancer. Besides Ras, 
numerous other proteins involved in the RTKs pathway are mutated in different cancer cells, 
indicating that these proteins retain a fundamental role in tumor development and 
progression. Considering the central function it is obvious that these molecules represent a 
fundamental channel for the development of novel drugs for cancer therapy.  
1.2 Apoptosis 
A key process profoundly influencing tumor progression is apoptosis. Apoptosis is the 
process of programmed cell death occurring in multicellular organisms and is characterized 
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by morphological changes including cell shrinkage, membrane blebbing, cromatine 
condensation and nuclear fragmentation. Factors such as cellular stress, oncogene activation 
and dysregulation of cell growth all lead to the activation of p53, which either arrest the cell 
cycle or activates apoptosis. Apoptosis regulates the proper tissue cell number eliminating 
damaged or excessive cells and it is also triggered by radiation and chemoterapeutic drugs 
used for cancer treatment (Sato et al., 1999). Two distinct intercommunicating apoptotic 
pathways have been described; the intrinsic and the extrinsic. The intrinsic pathway is 
activated following DNA damage and other severe cellular stresses. The intracellular signals 
hinge on the mitochondria with the release of cytochrome c which in turn binds to the 
cytosolic protein Apaf-1 to form the so called apoptosoma decisive for caspase activation. 
Caspases are a network of proteases that ultimately destroy the cellular structures and 
induce DNA fragmentation leading to cell death. The extrinsic apoptotic pathway is a 
receptor-mediated pathway and is activated by extracellular cues upon engagement of the 
so called death receptors by specific secreted ligands such as Apo2L/TRAIL. Upon 
activation the receptors for TRAIL activate the caspases specific of the extrinsic apoptotic 
pathway which ultimately leads to cell death (Jin & El-Deiry, 2005). 
1.3 Cells of the tumor microenvironment 
None of the cells of the tumor microenvironment except tumor cells are per se malignant; 
however the interactions with each other and directly or indirectly with the cancer cells may 
lead to the acquisition of an abnormal phenotype and expression pattern. Numerous studies 
have reported that the cells of the tumor microenvironment not only respond to and support 
carcinogenesis, but also can actively contribute to tumor initiation, progression, and 
metastasis. It has been demonstrated that stromal cells can cause transformation of the 
adjacent cells through transient signaling that, in some cases, leads to the disruption of 
homeostatic regulation, including control of tissue architecture, adhesion, cell death, and 
proliferation (Hu & Polyak, 2008). 
Fibroblasts in particular are important members of the stromal microenvironment, as they 
maintain the adjacent epithelia homeostasis through the secretion of growth factors and 
direct mesenchymal–epithelial cell interactions. It is becoming increasingly clear that 
fibroblasts are also prominent modifiers of cancer progression. Knowledge of the role of 
resting and activated fibroblasts in cancer is still evolving. A subpopulation of fibroblasts, 
the so-called cancer-associated fibroblasts (CAFs), is increasingly recognized as an 
important promoter of tumor growth and development. CAFs directly stimulate tumor cell 
proliferation and angiogenesis through paracrine secretion of growth factors, hormones and 
cytokines in a context-dependent manner (Rasanen & Vaheri, 2010). Many of the CAF-
secreted factors acting in isolation are sufficient to induce transformation of epithelial cells, 
indicative of a tumor-initiating capability of CAFs (Pietras & Ostman, 2010). Moreover CAFs 
can affect cancer progression by secreting and organizing altered ECM within the tumor 
stroma (Kalluri & Zeisberg, 2006).  
Inflammatory cells can also deeply affect cancer cells behavior. Tumor associated 
macrophages (TAMs), which represent the major inflammatory component of the stroma of 
many tumors, are strongly associated with tumor progression and metastasis. In contrast to 
the reactive macrophages which are characterized by a so-called M1 phenotype, TAMs are 
alternatively activated and acquire an M2 phenotype, thus promoting tumor growth, 
angiogenesis, metastasis, as well as suppressing potential anti-tumor immune activities. 
TAMs affect vascular density and ECM by secreting a vast array of pro-angiogenetic factors 
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and proteolytic enzymes including VEGF, FGF, PDGF, TNF-┙, MMPs, plasmin, urokinase-
type plasminogen activator (uPA) and the uPA receptor (uPAR) (Guruvayoorappan, 2008; 
Allavena et al., 2008). One key role for the microenvironment that has gained prominent 
recognition is neoangiogenesis. Tumors simply cannot progress without concomitant 
growth and organization of the stromal endothelial cells (EC) and pericyes. Malformed 
“leaky” tumor vessels contribute to tumor hypoxia, acidosis, and increased interstitial fluid 
pressure. The tumor in turn responds with a unique repertoire of gene expression, which in 
turn acts to alter cell growth, invasion, and ultimately metastasis (Li et al., 2007). 
1.4 Tumor angiogenesis and ECM 
Investigations into the roles of the tumor stroma have established that the ECM plays an 
important role in tumor vascularization (Wernert, 1997). Due to the accumulation of several 
gene mutations, cancer cells have the ability to be self-sufficient in growth signaling, 
insensitive to antigrowth signals, unresponsive to apoptotic events and capable of limitless 
replication. Although all of these neoplastic properties are necessary for tumor 
development, they are not sufficient to become clinically relevant malignancies, unless the 
tumor is able to recruit its own blood supply. In most tumors new blood vessels are formed 
through a process called angiogenesis, in which new blood vessels sprout from the 
preexisting vasculature (Folkman & Klagsbrun, 1987). Following EC proliferation newly 
formed vessels differentiate into arterioles and venules, necessary to provide blood supply 
to the growing tumors. In fact, solid tumors will not grow beyond the size of 1-2 mm, unless 
they induce the formation of new blood vessels to provide the oxygen and the nutrients 
necessary for their relentless growth and expansion (Campbell et al., 2010). During the 
different stages of angiogenesis, temporal and spatial regulation of ECM remodeling leads 
to local changes in net matrix deposition or degradation, which in turn contribute to control 
of EC growth, migration and differentiation. ECM remodeling is regulated by pro- and anti-
angiogenic factors, matrix-degrading proteases and cell-ECM interactions (Sottile, 2004). In 
this context discovering the roles played by novel ECM proteins in vascularization is a 
crucial step in the process of creating new treatments for pathological angiogenesis. 
1.5 ECM and tumor development 
The ECM composition and the stroma’s mechanical properties are other important 
characteristics that profoundly affect tumor cell behavior. The ECM tensile strength or 
stiffness can regulate cell growth, differentiation and migration, as well as the recruitment of 
other types of tumor-associated cells. Moreover, the stiffness and the increased interstitial 
pressure of the tumor stroma influences drug diffusion through the tumor and also the 
intrinsic drug sensitivity of malignant cells (Augsten et al., 2010). 
On the other end, tumor invasion and metastasis are accomplished through ECM 
breakdown mainly due to matrix metalloproteinases (MMPs) activation. The ECM 
disruption promotes abnormal inter- and intra- cellular signaling leading to dysregulation 
of cell proliferation, growth and cytoskeleton reorganization. In turn, the ECM degradation 
gives rise to an increase of growth factors and ECM-derived molecules that modulate the 
properties of the different tumor-resident cell types.  
An important event in tumor progression is the acquisition by cancer cells of the capability 
to dissociate from their original site and invade adjacent and distant tissues. Invasion 
involves the breaching of several barriers, including the basement membrane and the 
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stromal matrix. Tumor cell invasion and metastasis is a compelling issue of cancer treatment 
accounting for ~ 90% of cancer related deaths, hence the targeting of tumor invasion is 
increasingly recognized as a fundamental therapeutic approach. Other key elements of the 
tumor microenvironment are the single ECM components. The ECM is mainly composed by 
an intricate interlocking mesh of fibrillar and non-fibrillar collagens, elastic fibers, non-
collagenous glycoproteins such as proteoglycans (PGs) and glycosaminoglycans as 
hyaluronan (HA). Within these structural elements, the stroma is made also of matricellular 
proteins, a group of extracellular proteins that do not contribute directly to the formation of 
structural elements but serve to modulate cell-matrix interactions and cell function (Steeg, 
2006; Brooks et al., 2010). Tumors often display an altered ECM composition due to the 
factors produced by tumor and stromal cells. Most solid tumors exhibit a profoundly 
different ECM-protein profile compared to their normal counterparts. Many of these 
proteins, though the integrins or other cell surface molecules, affect tumor cells behavior in 
terms of proliferation, apoptotic rate and migration. 
2. Potential therapeutic targets 
2.1 Receptor tyrosine kinases 
RTKs are specifically activated by several extracellular molecules including growth factors, 
cytokines, and hormones. Most of the targeted inhibitors under development or already in 
clinical use are molecules with high affinity for growth factors RTKs, such as the Fibroblast 
Growth Factor Receptor (FGFR), the Vascular Endothelial Growth Factor Receptor (VEGFR), 
the Platelet-Derived Growth Factor Receptor (PDGFR), the tyrosine-protein kinase Kit 
receptor (c-Kit) and the Epidermal Growth Factor Receptor (EGFR). The FGF family 
contains 22 related peptides able to bind four different FGF receptors (FGFR 1-4). FGFs have 
been implicated in both physiological and pathological angiogenesis, vasculogenesis and 
blood vessel remodeling, influencing proliferation and differentiation of different cell types. 
FGF2 (aka bFGF) is a potent mitogen and chemotactic factor for endothelial and smooth 
muscle cells and stimulate pericyte formation. It also stimulates the production of the 
urokinase-type plasminogen activator (uPA) and MMP expression inducing vessel 
destabilization and ECM breakdown. Receptor dimerization and the presence of heparin or 
heparan sulfate proteoglycans are necessary for its activation as well as internalization of the 
ligand to achieve full activation. FGFR1 is the best characterized FGF receptor and it was 
found to be amplified in 8-10% of breast cancers (Elbauomy et al., 2007). FGFR1 is over-
expressed and occasionally amplified also in oral and esophageal squamous carcinomas 
(Ishizuka et al., 2002)), prostate cancer (Sahadevan et al., 2007), and in a number of bladder 
carcinomas (Simon et al., 2001). Amplifications have also been observed in ovarian tumors 
(Gorringe et al., 2007). The EGFR/ERBB family was one of the first to be linked to cancer 
development and progression. EGFRs regulate cell proliferation, migration and 
differentiation. Moreover, their signaling is a key driver of the Epithelial-Mesenchimal 
Transition (EMT) which is a major event involved in the metastatic dissemination of tumor 
cells (Wilkins-Port & Higgins, 2007). The EGFR family comprises four different receptors, 
EGFR/HER1 (ERBB1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4) and all of them 
have been implicated in the development of several tumor types. The EGFR downstream 
signaling cascade includes the Ras-MAP kinase pathway (Herbst, 2004). Over-expression of 
EGFRs or mutations in their downstream pathways has been linked to poor response to 
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chemotherapy whereas its correlation with prognosis has not been demonstrated due to 
contrasting results.  
VEGF is an essential growth and survival factor for ECs promoting their survival, 
proliferation, migration and morphogenesis into functional tubular structures. Moreover, its 
activity influences vascular permeability (Roskoski, Jr., 2007). The critical role of VEGF in 
the formation of a new vasculature in growing tumors with the recruitment of circulating 
ECs and progenitor cells to the sites of neovascularization is well known and plays an 
important role in tumor progression (Folkman, 1971). In several tumor types including 
colorectal cancer, VEGF expression has been linked with tumor aggressiveness, poor 
disease-free and overall survival, distant metastatic spread and decreased response to 
preoperative radiotherapy (Giatromanolaki et al., 2006; Giralt et al., 2006; Nozue et al., 2001; 
Zlobec et al., 2005). There are five human VEGF family members and three VEGF receptors. 
Each VEGF molecule displays a characteristic receptor binding pattern; VEGF-A binds to 
both VEGFR1 and VEGFR2; VEGF-B and PlGF (Placental Growth Factor) bind to VEGF1, 
instead VEGF-C and VEGF-D bind to VEGFR3. The activation of VEGFR2 though the 
binding VEGF-A plays a pivotal role in the regulation of EC function and angiogenesis and 
for this reason VEGFR2 is one of the most studied receptors of this family. Another 
important cytokine is the PDGF which is involved in the control of the proliferation, 
survival and motility of several mesenchymal cell types.  
In addition, it is important for the maintenance of the perivascular structures that surround 
and support tumor blood vessels. For this reason PDGF receptors are under investigation as 
targets for anti-angiogenic cancer therapy. Two isoforms of the PDGF receptors are known, 
PDGFR┙ and PDGFR┚. Both can form homo- or heterodimers and stimulate cell 
proliferation, but only PDGFR┚┚ and PDGFR┙┚ dimers can mediate smooth muscle cell and 
fibroblast chemotaxis. After their activation PDGF receptors activate the Ras/MAPK 
pathway modulating cell proliferation, migration and differentiation and the PI3K/AKT 
pathway promoting cell survival. Another member of the PDGFR family is KIT, which was 
shown to be over-expressed in many tumors, including gastrointestinal stromal tumors 
(GISTs), mast cell tumors, melanomas, endometrial and ovarian carcinomas and small cell 
carcinomas of the lung. The binding of stem cell factor to KIT induces receptor dimerization 
and activation of the intracellular signaling mediated by the PI3K, Ras/MAPK, JAK/STAT 
pathways to stimulate cell survival (Sattler & Salgia, 2004). 
2.2 Apoptotic molecules 
The life and death decision at the cellular level is controlled by environmental cues 
including the presence or absence of growth factors and physical stimuli such as mechanical 
stress or radiation. Moreover, cells sense their three dimensional location through specific 
interactions with the ECM as well as with neighboring cells and these contacts are essential 
for cell survival. In particular, the lack of appropriate cells/ECM interactions leads to a 
peculiar form of cell death named anoikis (Gilmore, 2005). The life and death decision is also 
profoundly influenced by the components of the ECM, which can change dynamically 
during differentiation, development and other tissue-remodeling events. As mentioned 
above, cells’ anchorage is essential for survival (Meredith, Jr. et al., 1993) which is 
maintained through the activation PI3K Kinase-AKT pathway granted by integrin 
engagement; should this interaction be disrupted cells undergo apoptosis (Frisch & 
Screaton, 2001). For example the use of competitors for integrin binding such as Arginin, 
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Glicine, Aspartate-based (RGD-based) peptides can induce apoptosis by directly activating 
caspases (Adderley & Fitzgerald, 2000). ECs are highly susceptible to survival anchorage 
dependent stimuli (Scatena et al., 1998). As mentioned, also the loss of cell-cell contacts leads 
to the activation of a default death programmed in a variety of cell types. For instance, 
deficiency or truncation of VE-cadherin which mediates adhesion between ECs (Hermiston 
& Gordon, 1995) induces ECs’ apoptosis and abolishes transmission of the survival signal by 
VEGF-A to AKT Kinase and Bcl2 (Carmeliet et al., 1999) and this profoundly affects the 
angiogeneic potential. Given the importance of adhesion in maintaining cell survival, 
altered expression of glycoproteins in the tumor microenvironment leads to an impairment 
of cell survival. For example, PGs expression is markedly altered during malignant 
transformation and tumor progression and is influenced by cancer cells-derived secreted 
factors and this may either facilitate or counteract the growth of solid tumors. PGs, such as 
versican, perlecan and small leucine-rich PGs affect cancer cell signaling, growth and 
survival, as well as cell adhesion, migration and angiogenesis. Furthermore, expression of 
cell-surface-associated PGs, such as syndecans and glypicans, is also modulated in both 
tumor and stromal cells. Cell-surface-associated PGs bind various factors that are involved 
in cell signaling, thereby affecting cell proliferation, adhesion and motility. An important 
mechanism of action is offered by a proteolytic processing of cell-surface PGs known as 
ectodomain shedding of syndecans; this facilitates cancer and EC motility, protects matrix 
proteases and provides a chemotactic gradient of mitogens. However, syndecans on stromal 
cells may be important for stromal cell/cancer cell interplay and may promote stromal cell 
proliferation, migration and angiogenesis. The abnormal PG expression by cancer and 
stromal cells may be exploited to evaluate tumor progression and patient survival 
(Theocharis et al., 2010). It is known that heparan sulphate proteoglycans (HSPGs), 
represent an important reservoir of chemochines, cytochines and enzymes (Bishop et al., 
2007; Sasisekharan et al., 2002). Heparanase, can cleave HS side chains from HSPGs and 
release a multitude of bioactive molecules including bFGF and Hepatocyte Growth Factor 
(HGF) (Ogasawara et al., 1996). bFGF enhances EC and tumor cell proliferation and this was 
demonstrated to contribute to hepatocellular carcinoma progression (Pang & Poon, 2006). 
Heparanase expression is closely related with apoptosis of several tumors cells, including 
HCC (Ikeguchi et al., 2003b; Ginath et al., 2001) and there is a significant positive correlation 
between the mRNA expression levels of heparanase and the percentages of apoptotic 
hepatocytes in liver tissues (Ikeguchi et al., 2003a). Besides affecting EC proliferation bFGF is 
also responsible for a direct effect on tumor cells protecting them from apoptosis. Cell 
surface HSPGs act as co-receptors for formation of high-affinity bFGF-receptor complexes, 
and in this context the HS chains play a leading role (Chua et al., 2004). In this context, the 
heparanase-induced alteration of cell surface HSPGs, might down-regulate bFGF pro-
survival effects resulting in tumor cell apoptosis. In addition, there is also a group of ECM 
molecules that have been shown to directly impair cell viability. Among these proteins 
CCN1, a secreted ECM-associated heparin binding protein, can either induce or suppress 
apoptosis: it can promote EC survival but also induce fibroblast apoptosis mediated by 
integrin ┙6┚1 and the heparan sulfate proteoglycan sydecan 4. The mechanism involves the 
activation of Bax which leads to cytochrome-c release and activation of caspase-9 and -3 
activation (Todorovicc et al., 2005).  
Another ECM protein playing, among other functions in tumor development, an active role 
in the control of apoptosis is the Secreted Protein Acidic and Rich in Cystein (SPARC). 
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SPARC is an important regulator of cell growth and malignancy and enhances apoptosis in 
various tumors including ovarian cancer, where its absence significantly diminished cell 
death. The mechanism is still elusive but involves the activation of caspase-8, the initiator 
caspase of the extrinsic apoptotic pathway independently of death receptor activation and 
leads to downstream involvement of Bid. Interestingly, this effect results from the 
interaction between SPARC and the N-terminus of the procaspase-8 DED-containing 
domain (Tang & Tai, 2007). The secreted small leucine-rich proteoglycan decorin has also 
been shown to inhibit cancer growth by impairing EGFR function and triggering apoptosis 
through caspase-3 activation (Seidler et al., 2006).  
EMILIN2, another ECM glycoprotein, adopts a peculiar mechanism in affecting tumor 
development and apoptosis. Elastin Microfibril Interface-Located proteINs (EMILINs) 
constitute a family of ECM glycoproteins characterized by the presence of an EMI domain at 
the N-terminus and a gC1q domain at the C-terminus (Doliana et al., 2000; Mongiat et al., 
2000). Recent studies show that this molecule affects tumor cell survival leaving normal cells 
unharmed; the mechanism involves the direct activation of the death receptors and in 
particular DR4. The activation of the extrinsic apoptotic pathway leads to a dramatic 
decrease of tumor cell viability associated with DNA fragmentation and caspase-8 and 
caspase-3 activation. More recently a discrete sequence of this molecule was found to be 
involved in these anti-tumorigenic effects (Mongiat et al., 2007; Mongiat et al., 2010). 
2.3 Cells of the microenvironment 
Cancer associated fibroblasts (CAFs) Several studies have demonstrated that normal fibroblasts 
contribute to maintaining epithelial homeostasis by suppressing proliferation and oncogenic 
potential of adjacent epithelia. Once they are recruited to the tumor, most of them switch to 
a permanently activated phenotype, and become CAFs. The phenotype of CAFs resembles 
that of normal fibroblasts during wound healing where they are activated and generate 
ECM components and pro-inflammatory cytokines. After the wound is healed, the normal 
phenotype is restored; on the contrary, in the tumor microenvironment their status remains 
permanently activated and for this reason tumors are frequently termed as “wounds that do 
not heal”. By creating an altered microenvironment through the overexpression of cytokines 
such as TGF┚, PDGF, FGF and connective tissue growth factors, a growing tumor can co-opt 
fibroblasts and turn them into CAFs (Erez et al., 2010).  
CAFs are not only target cells whose activity is modulated by environmental factors, but 
also active cells that significantly contribute to tumorigenesis and metastasis. Abundant 
growth-promoting factors have been found in the conditioned media of CAFs isolated from 
metastatic colon cancer patients, compared to the conditioned media taken from normal 
skin fibroblasts (Xing et al., 2010). In addition, CAFs are able to induce epithelial cells 
transformation following injection of normal human breast epithelial cells mixed with 
irradiated or not-irradiated fibroblasts in immunocompromised mice (Kuperwasser et al., 
2004). The tumorigenic potential of CAFs depends also on the production of the mutagenic 
reactive oxygen species (ROS) under conditions of pH and hypoxia that characterize the 
tumor microenvironment. CAFs are known to produce Insulin-like Growth Factor-1 and -2 
(IGF-1 and -2), thus promoting tumor growth providing survival signals allowing tumor 
cells to evade programmed cell death. CAFs are also supporters of tumor angiogenesis 
being an important source of VEGF (Li et al., 2007). Finally, CAFs produce high levels of the 
Stomal cell-Derived Factor 1┙ (SDF-1┙), the ligand of C-X-C chemokine Receptor type 4 
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(CXCR4), which is highly expressed by cancer cells. Once activated, CXCR4 can promote 
mammary epithelial proliferation, migration and invasion and angiogenesis (Orimo et al., 
2005).  
Another important role of CAFs is their active participation in ECM remodeling during 
tumor development. The increase production of fibronectin, collagens, proteoglicans and 
glicosaminoglicans promote survival stimuli from integrin engagement and impair 
apoptosis induced by chemotherapeutic drugs. Another event affecting the drugs uptake is 
the increased interstitial fluid pressure. The deposition of a dense ECM network leads to 
fibroblasts’ proliferation which may acquire a contractile phenotype to become 
myofibrobrast. This results in a constant increase in tension within the tumor connective 
network and increase of interstitial fluid pressure leading to an impaired uptake of 
therapeutic agents (Bouzin & Feron, 2007). 
It has been demonstrated that in some cases increased fibronectin expression correlates with 
tumorigenicity amplifing integrin survival signaling (Han et al., 2004; Marastoni et al., 2008). 
Collagen I also contributes to the decrease of the uptake and regulates the sensitivity of 
tumor cells to these drugs. 
The ECM remodeling by MMPs is one of the most crucial steps for cancer progression where 
the equilibrium between MMPs and their inhibitors is completely disrupted. It has been 
shown that CAFs secrete various matrix-degrading proteases as well as their activators such 
as uPA, thus promoting tumor invasion. The breakage of the basement membrane allows 
the epithelial cancer cells to intravasate into the circulation system and also in this context 
the cross-talk between the cancer cells and CAFs seems to be crucial.  
Tumor associated macrophages (TAMs) and inflammatory cells. It is known that tumors are 
generally infiltrated by immune cells with which the host tries to contrast tumor 
progression, a process known as immune surveillance. Several studies report a correlation 
between the inflammatory infiltrates and an improved prognosis or a better lifespan for 
patients. However, some evidences contradict this paradigm identifying the presence of 
immune cells as a negative prognostic factor particularly for breast, prostate, ovarian and 
cervical cancers (Whiteside, 2007). The association between a chronic inflammation and 
cancer was first formulated by Dr. Virchow in 1863. This concept has been recently 
reconsidered when specific inflammatory cell types and in particular TAMs, the major 
inflammatory component of the stroma of many tumors, have been associated to neoplastic 
transformation (Houghton, 2010). In less than 10% of the cases, the presence of TAMs is 
associated with good prognosis. A possible explanation to this apparent paradox is that 
tumor cells are able to recruit immune cells and, similarly to what happens with CAFs, to 
activate their status. The cytokine profile in the tumor microenvironment is considered 
extremely important in determining the phenotype of the local inflammatory cells (Pollard, 
2004). 
Compared to reactive macrophages, TAMs are alternatively activated, acquiring an M2 
phenotype, thus promoting tumor growth, angiogenesis, metastasis and suppressing 
potential anti-tumor immune activities, a phenomenon known as immunoediting.  
A central event determining TAMs activity is NF-kB activation. In response to different pro-
inflammatory signals TAMs display defective NF-kB activation that causes impaired 
expression of cytotoxic mediators, such as Nitric Oxide (NO), Tumor Necrosis Factor ┙ 
(TNF┙), and Interleukin 1 and 12 (IL1 and IL12), (Mantovani et al., 2006). In a normal tissue, 
pathogenic infection or a wound healing triggers the local expression of an array of 
inflammatory cytokines and growth factors, such as Colony Stimulating Factor 1 (CSF-1), 
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Granulocyte–Macrophage CSF (GM-CSF), Macrophage-Stimulating Protein (MSP) and 
Transforming Growth Factor ┚1 (TGF-┚1). These factors, together with the products of tissue 
breakdown, recruit circulating monocytes which are stimulated to differentiate into 
macrophages. Macrophages, in turn, mediate immune responses, kill pathogens, stimulate 
angiogenesis and participate in tissue repair (Pollard, 2004). This physiological phenomenon 
is uncontrolled in tumors given the persistent stimuli from both tumor cells and CAFs. CSF-
1, the main growth factor responsible for survival, proliferation, differentiation and 
chemotaxis of macrophages, is over-expressed in different types of cancers. In addition 
tumor-derived anti-inflammatory molecules such as IL4, IL10, TGF┚-1, and prostaglandin 
E2 are essential for TAMs’ function and this finding suggested that exposure to IL4 and IL10 
may induce monocytes to develop into polarized M2 macrophages (Mantovani et al., 2002).  
TAM infiltration positively correlates with tumor cell proliferation in breast, endometrial 
and renal cell carcinoma. In fact, various studies have shown that these cells express a 
number of factors that stimulate tumor cell proliferation and survival, including EGF, 
PDGF, TGF-┚1, HGF, and bFGF. TAMs are also important supporters of tumor angiogenesis 
being a source of VEGF; TAMs cluster in avascular areas, recruited by chemokines that are 
secreted in response to hypoxia. This condition up-regulates hypoxia-inducible factor-2┙ 
(HIF-2┙) which, in turn, induces VEGF expression. VEGF expression by TAMs is induced by 
CSF-1 and the cytokine in a positive feedback loop recruits other macrophages thus 
increasing the rate of vascularization (Lewis & Pollard, 2006). TAMs also produce other pro-
angiogenetic factors and proteolitic enzymes including IL8, FGF, PDGF, TNF-┙, MMP-2, 
MMP-7, MMP-9, MMP-12, and cyclooxygenase 2 (COX-2) (Lewis & Pollard, 2006). TAMs 
enhance the invasive capacity of cancer cells (Lewis & Pollard, 2006). This effect may 
depend on the expression of MMPs and uPA and its receptor uPAR which enhances the 
motility and invasion of cancer cells (Guruvayoorappan, 2008). 
Neutrophils. Once recruited to the tumor microenvironment, neutrophils have also been 
demonstrated to change their phenotype and promote tumor progression. Various 
transgenic mice models and clinical data show that the presence of tumor-associated 
neutrophils often correlates with poor prognosis, given their ability to stimulate tumor 
growth, angiogenesis and metastasis. IL8, which is frequently over-expressed by tumor and 
stromal cells, is a strong chemokine for neutrophils, which express the IL8 receptors CXCR-1 
and -2. Once inside the tumors, neutrophils can secrete factors such as HGF and oncostatin 
M which induces tumors cells to enhance the VEGF expression and increases their 
invasiveness. IL8 also stimulates neutrophil degranulation with the release of MMP9 
(Gregory & Houghton, 2011; Murdoch et al., 2008). 
Neutrophil elastase (NE) is an important protease released by neutrophils. Recent data show 
that it promotes tumor growth via an alteration of tumor cell signaling that ultimately leads 
to PI3K hyperactivity (Gregory & Houghton, 2011; Houghton, 2010). Reactive Oxygen 
Species (ROS) produced by neutrophils as a host defense against microorganisms could act 
as pro-tumorigenic agents. As CAFs and TAMs, neutrophils can also facilitate tumor cells 
metastasis. It is likely that the neutrophils phenotypic switch, which is defined N1-N2 
polarization similarly to the M1-M2 polarization of macrophages, is mediated by the key 
cytokine TGF┚ (Fridlender et al., 2009).  
Tumor ECs and pericytes. Vessels are a requisite for tumor growth and also are necessary for 
tumors to metastasize. Thus, the ability to recruit vessels is an important and growth 
limiting step for tumors. The release of pro-angiogenetic factors in the tumor 
microenvironment results in the recruitment and enhanced proliferation of ECs. Members of 
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VEGF family and their receptors are considered the major key mediators of angiogenesis. 
The binding of VEGF to VEGFR triggers an intracellular signaling that is mainly mediated 
by MAPK and PI3K/Akt/mTOR pathways. This results in the expression of HIF-1┙ and 
induction of PDGF, FGF, G-CSF, TGF┚ and angiopoietins, thus enhancing angiogenesis 
(Boehm et al., 2010).  
Another important cellular component of the blood vessels are pericytes whose recruitment 
is highly dependent on PDGF┚-R expression as well as on the production of PDGF┚ ligand 
by ECs (Pietras & Ostman, 2010). Tumor pericytes are rarely dispersed and loosely along the 
vessels compared to their normal counterparts and their role in tumor development is not 
yet well defined. Some studies have demonstrated that increased coverage of pericytes 
enhances tumor growth, by promoting neo-vascularization. In contrast, other cancer models 
show a pericyte-mediated angiostatic effect, thus the outcome of pericyte-derived signals 
appears to be highly context dependent (Pietras & Ostman, 2010). 
2.4 ECM proteins and tumor angiogenesis 
The network of fibrous proteins and glycosaminoglycans (GAGs) of the ECM affects tumor 
vessel formation both in direct and indirect way. The GAGs carbohydrate polymers of the 
proteoglycans are involved in both keeping the ECM and surrounding cells hydrated and 
trapping and storing growth factors. Therefore, GAG molecules may exert a variety of 
regulatory effects on the accessibility of angiogenic factors (Rouet et al., 2005). Heparan 
Sulfate (HS) GAGs include the syndecans, glypicans, perlecans and agrins. HSGAGs that are 
present on the EC surface have the ability to either inhibit or promote neovascularization by 
mediating signalling through VEGF receptors (Iozzo & San Antonio, 2001) or bFGF (Walker 
et al., 1994).  
Most of the ECM proteins, such as fibronectin, collagen and laminin, mediate angiogenesis 
through integrin-binding RGD motifs. In a resting quiescent state ECs exhibit the lowest cell 
mitotic index of all the cells of the body (Folkman, 2006). Induction of angiogenesis and 
ECM remodeling is characterized by an increased proliferation and permeability as well as 
cytoskeletal and cell-to-cell contact changes which results in newly formed focal contacts 
primarily mediated by integrins. Fibronectin is produced by both activated ECs and smooth 
muscle cells (SMC), and its levels are augmented during angiogenesis as fibronectin leaks 
from the blood due to the increased vascular permeability. The RGD domain of fibronectin 
binds to the integrin ┙5┚1, which is markedly up-regulated during angiogenesis and is over-
expressed in ECs within the tumors. The collagen integrin receptors ┙1┚1 and ┙2┚1 also play 
a positive role during angiogenesis. Moreover, ┙1 chain laminin peptides mediate 
angiogenesis in vitro (Malinda et al., 1999). As previously mentioned, the proteolytic activity 
triggered during angiogenesis facilitates degradation of the basement membrane, matrix 
remodeling and cell migration and invasion which are essential for the development of 
novel blood vessels, hence this process is tightly regulated. There are two major classes of 
enzymes: the PA/plasmin system and MMPs. There are at least 20 members of the MMP 
family most of them being implicated in tumorigenesis and a large number of these 
proteases degrade the vascular basement membrane and matrix in order to allow vascular 
sprouting (Pepper, 2001). The activity of these proteases is regulated by endogenous tissue 
inhibitors of metalloproteinases (TIMPs) which generally display anti-angiogenic properties. 
By degrading the matrix, MMPs not only provide physical space within the matrix for cell 
migration, but also provide ECs with proliferation and differentiation signals due to the 
release of cryptic sites present on ECM molecules and the release of soluble growth factors. 
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Various MMPs cleave heparin bound growth factors such as VEGF and bFGF, thus 
stimulating the formation of new blood vessels (Lee et al., 2005; Hawinkels et al., 2008). 
Stromal recruitment of fibroblasts and immune cells such as macrophages can also affect 
angiogenesis as analyzed above. Recently it was found that loss of PTEN signaling in 
stromal fibroblasts results in the induction of ECM remodeling through the increase of the 
transcriptional factor Ets2 which is an upstream target of MMP-9 (Trimboli et al., 2009). 
Protease-mediated cleavage of the ECM also results in the release of cryptic domains that 
regulate angiogenesis. Cleavage of collagen XVIII and the ┙1, ┙2 and ┙3 chains of collagen 
IV release the angiogenic inhibitors endostatin, arrestin, canstatin and tumstatin, 
respectively (Kalluri, 2003). For this reason MMP inhibitors have an impact on tumor 
angiogenesis. For instance, TIMP-1 over-expression suppresses tumorigenesis, in part due to 
its effects on the tumor vasculature. Treatment of ECs with TIMP-1 alters the formation of 
tubules on Matrigel while proliferation is not affected. TIMP-2 decreases EC’ proliferation 
and inhibits angiogenesis in vivo (Seo et al., 2003). TIMP-3 has also been shown to decrease 
angiogenesis, particularly through EC disaggregation and impairment of Matrigel 
tubulogenesis (Chetty et al., 2008).  
Another group of ECM proteins which have been recently linked to tumor angiogenesis are 
the membrane-associated disintegrin and metalloproteinases (ADAMs), including those 
carrying Thrombospondin Motifs (ADAMTs) which are instead secreted in the 
microenvironment (Dunn et al., 2006). These proteins regulate angiogenesis directly or 
through expression of MMPs. For instance, ADAM-17 alters EC’ morphology of decreases 
cell proliferation. ADAMTS1 and ADAMTS8 contain the thrombospondin antiangiogenic 
domain (TSR1) and inhibit EC proliferation and suppress growth factor induced 
vascularization (Vazquez et al., 1999).  
The Bone Morphogenic Proteins (BMPs) have also gained recognition for their potential role 
in tumor angiogenesis. BMPs belong to the TGF┚ superfamily of proteins and were found to 
influence angiogenesis by stimulating the secretion of proangiogenic growth factors such as 
VEGF (Deckers et al., 2002). BMP expression correlates with increased EC migration and 
tubulogenesis on Matrigel (Rothhammer et al., 2007). The role of BMPs in angiogenesis is 
controversial and some reports demonstrate an anti-angiogenic effect. Further 
understanding of the role played by BMPs in the ECM and tumor angiogenesis will benefit 
therapeutic studies which target angiogenesis, tumour growth, and metastatic spread of 
disease. 
2.5 ECM proteins involved in invasion and metastasis 
The main cause of cancer related deaths is the metastatic disease, which is due to the 
widespread dissemination is often impossible to successfully eradicate. Metastasis results 
from a complex molecular cascade comprising many steps, all of which are interconnected 
through a series of adhesive interactions and invasive processes as well as responses to 
chemotactic stimuli, through which cancer cells leave the site of the primary tumor mass 
and disseminate to distant anatomic sites where they proliferate and form secondary tumor 
foci. To complete this process tumor cells must invade the tissue surrounding the primary 
tumor, enter either the lymphatics or the bloodstream, survive and eventually arrest in the 
circulation, extravasate into a tissue and grow in the new site. A crucial element in the 
metastatic process is the ECM whose composition, structure and biophysical forces exerted 
may influence cell invasion and migration.  
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ECM and invasion. Most solid tumors exhibit a distinctive ECM-protein profile, compared to 
the normal counterparts and many of these proteins interact directly with tumor cells 
influencing their migration and invasion ability. A number of proteins, such as tenascin-C 
(TNC), fibronectin, and SPARC are consistently up-regulated in tumors (Allen & Louise, 
2011). TNC is a multifunctional protein expressed at low levels in normal adult tissues but 
over-expressed in conjunction with cell migration occurring for instance during 
embryogenesis, wound healing or cancer development. TNC is highly expressed in a variety 
of invasive and metastasizing cancers, including breast, colon, lung and brain (Guttery et al., 
2010). Multiple alternatively-spliced isoforms of TNC are known and seem to be tumor-
specific. For example, the full length protein is expressed in pancreatic and prostate cancers, 
while in breast and ovarian carcinomas the domain A and D containing isoforms are the 
most abundant. Besides its composition, also the tensile strength of ECM can regulate 
epithelial cell growth, transformation and migration; the tumor-associated stroma is usually 
more stiff than the normal tissue, and this peculiar characteristic of the tumor 
microenvironment may influence tumor progression (Tilghman et al., 2010). For example, 
the reduction of ECM stiffness can inhibit the malignancy of transformed mammary 
epithelial cells (Allen & Louise, 2011). One way in which tensile strength can be modulated 
is the cross-linking of collagens and elastin due to lysil oxidase activity (LOX). Studies 
conducted using mouse models of breast cancer allowed to correlate the high LOX 
expression, increased collagen cross-linking and elevated ECM stiffness with the invasive 
progression of the disease. The role of LOX has been well established in colorectal (Baker et 
al., 2011) and breast (Erler & Giaccia, 2006) cancer progression, in this last case it was 
demonstrated that hypoxic primary tumor cells increase LOX expression and secretion, 
enabling cell movement to more oxygenated and thus nutrient-rich areas. LOX increases cell 
invasion and migration through regulation of cell-matrix adhesion and focal adhesion 
kinase (FAK) activity. LOX may be involved in the cell-matrix adhesion interactions 
required for intravasation and extravasation and, finally, is required for the formation of a 
mature ECM at the secondary site, allowing survival signaling and possibly bone marrow 
derived cells recruitment. 
The fibrillar collagens surrounding tumors are often remodeled and this is associated with 
the metastatic progression. The linearization and reorientation of collagen fibers at the 
invasive front of cancer cells is a classic example of malignant transformation and metastatic 
dissemination (Cox & Erler, 2011). 
In most human tumors there is abundant accumulation of HA. A large number of studies 
performed during the last three decades have demonstrated a close correlation between 
malignancy and hyaluronan-rich ECM, as well as with the expression of some specific 
variants of its CD44 receptor (Misra et al., 2011). The CD44 present at the surface of cancer 
cells interacts with HA-rich microenvironments, thus affecting cell signaling pathways and 
enabling malignant cells to migrate, invade basal membranes and ECM and to lodge at 
distant sites from the primary tumor. The HA content in the tumor stroma impacts on the 
overall outcome of the disease and correlates with tumor grade and poor prognosis. HA, 
HA synthetases, hyaluronidases and HA receptors are involved in a wild range of 
carcinomas, as breast, lung, skin, and gastrointestinal (Sironen et al., 2011).  
Cell-cell and cell-ECM interactions. Invasion, which characterizes the metastatic process, 
consists of changes in tumor cell adherence to the other cells and to the ECM and is 
accompanied by the proteolytic degradation of the surrounding tissue and by the motility 
that propels tumor cells through the tissue.  
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Loss of cell-cell adhesion within the primary tumor mass permits disaggregation of tumor 
cells and hence aids the initial dissemination. Compared with normal epithelial cells, cancer 
cells show diminished cell-cell adhesiveness, due to the alteration of cadherin/catenin 
expression. The process leading from a polarized epithelial non-motile phenotype to a more 
motile and non-polarized phenotype is called epithelial to mesenchymal transition (EMT). 
This event is associated with the cadherin switch consisting in the loss of E-cadherin 
expression, normally present on the epithelial cell surface, and the gain of N-cadherin 
expression which associates with a metastatic phenotype. The loss of E-cadherin expression 
has been shown in several types of epithelial cancers including breast, gastrointestinal, lung, 
stomach, prostate, and kidney (Hazan et al., 2004).  
The interaction between tumor cells and the stroma is mostly mediated by integrins, which 
not only mediate cell-ECM adhesion, but also play a role in intracellular signaling 
stimulating events as proteolysis and angiogenesis (Brooks et al., 2010). Integrins are 
emerging as important factors in metastatic progression and their expression levels correlate 
with pathological outcomes, for example colon, breast and prostate cancers often display 
altered integrin expression which can vary considerably between normal and tumor tissues 
(Desgrosellier & Cheresh, 2010). Most notably, integrins ┙V┚3, ┙5┚1 and ┙V┚6, are expressed 
at low levels in most adult epithelia but can be highly up-regulated in tumors. On the other 
end, ┙2┚1, is down-regulated in cancer leading to an increase of tumor cell dissemination; 
when this integrin is re-expressed in breast cancer cells, the phenotype is reverted, 
suggesting that it behaves as a tumor-suppressor integrin.  
Proteases. The engagement of integrins and other adhesion molecules is accompanied by the 
recruitment of proteases which degrade the ECM and help providing a pathway for 
invasion. During the metastatic dissemination of tumor cells, the degradation of 
components of the ECM is achieved through the action of several hydrolytic enzymes which 
are released either by the tumor cells themselves or by cells surrounding the tumor. The 
enzymes play a role during metastasis include MMPs, cathepsines, uPA and heparanases. 
All these molecules once exogenously over-expressed increase cell invasion (Brooks et al., 
2010). The proteolityc activity of these enzymes facilitates the migration of tumor cells in 
different ways; physical barriers of dense matrix are removed, latent proteases, growth 
factors and chemotactic agents are often activated, integrin-binding sites within the ECM 
molecules are exposed and transmit migratory and survival signals, finally bioactive ECM 
fragments are generated as, for example, from collagen IV and laminin-5 (Geho et al., 2005). 
The expression and role of the different MMPs is quite diverse during cancer progression. 
They can promote or inhibit cancer development depending on the tumor stage, tumor site, 
enzyme localization and substrate profile. For example, MMP-9 functions as a tumor 
promoter during carcinogenesis but at later stages of the disease and under specific 
conditions it can also function as an anticancer enzyme (Gialeli et al., 2011).  
Another important regulator of tumor invasion is the uPA system consisting of the specific 
protease uPA and its cellular receptor uPAR. The enzyme is released by tumor or tumor-
associated cells, it binds to the receptor leading to plasmin activation. This mechanism 
results in the amplification of ECM proteolysis by both the degradative ability of plasmin 
and the initiation of an activation cascade involving MMPs. Elevated levels of uPA have 
been reported in many types of cancer, and anti-uPAR targeting therapy is currently being 
attempted (Brooks et al., 2010). 
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The pre-metastatic niche. Once tumor cells reach the secondary site, they undergo apoptosis, 
lie dormant or proliferate to form the secondary tumor. Recent evidences suggest that 
distant sites, called pre-metastatic niches, may be pre-conditioned to become a fertile 
ground for the establishment of metastasis (Coghlin & Murray, 2010). Hematopoietic cells 
migrate through the tissues and cause the remodeling of the ECM and growth factors 
milieu. Such altered microenvironment can attract tumor cells and support their 
proliferation (Brooks et al., 2010). Elevated fibronectin expression by resident fibroblasts at 
the pre-metastatic site represents a critical factor in the development of the pre-metastatic 
niche. The key tumor-secreted factors that determine the formation of this niche have yet to 
be identified, although TNF, TGF-┚ and VEGF are likely to be involved (Erler et al., 2009). 
ECM remodeling enzymes like MMPs and LOX seem to play a role also in the pre-metastatic 
niche formation. For example, the primary tumor-driven VEGFR-1 activation is required for 
the secretion of MMP-9 by the ECs and macrophages, thus deeply affecting the metastatic 
environment of the lungs. This is thought to make the lung microenvironment more 
hospitable for the subsequent invasion and survival of metastatic cells. The activity of 
tumor-secreted LOX is essential for the recruitment of bone marrow derived cells, because 
of ECM remodeling and MMPs’ activation induced by collagen cross-linking. Exactly what 
determines the site of the pre-metastatic niche remains elusive, although some recent studies 
have proposed that they might occur in sites exposed to frequent mechanical strain (Cox & 
Erler, 2011).  
3. Therapeutic strategies 
3.1 Receptor tyrosine kinase inhibition 
Given the critical role that RTKs play in signal transduction profoundly affecting tumor 
progression, several molecules to block the aberrant activation of these pathways have been 
developed (Zwick et al., 2002). Due to the high level of complexity of these pathways, 
investigators have attempted to interfere at different levels of the signaling cascade, from 
the extracellular ligands, to the membrane receptors, to the intracellular non-receptor 
tyrosine kinases (Fig.2). Several modalities are currently employed to inhibit kinase activity 
such as small inhibitors, molecular antibodies, but also peptide mimetics and antisense 
oligonucleotides (Dancey & Sausville, 2003; Imai & Takaoka, 2006).  
Small molecule tyrosine kinase inhibitors - Tyrosin kinases are present in an active or inactive 
form. Active kinases are characterized by high structural homology whereas the structures 
of the inactive forms are dissimilar. This characteristic suggests that molecules able to 
recognize and bind to the inactive form of the enzyme, could present higher efficacy because 
of lower cross-reactivity and increased specificity. Despite the fact that more specific 
inhibitors allow to precisely control cellular activity, several studies have demonstrated the 
importance of inhibiting multiple critical nodes in order to increase treatment response. 
Most cancers in fact are characterized by multiple aberrant signaling pathways and thus 
may require inhibition of a number of signaling endpoints for an optimal response. In 
addition, the ability of multi-targeted drugs to inhibit different kinases can represent an 
advantage in case of the development of drug resistance. In some occasions cells treated 
with a selective kinase inhibitor activate alternative pathways to maintain their activity. 
Hence, a chemical compound able to simultaneously inhibit several kinases bares the 
potential to be less prone to drug resistance. On the other hand, the use of multitargeted 
inhibitors is usually accompanied by worse side effects and limits on the maximum dose 
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that can be used for treatment, thus limiting the real benefits. Most of the small molecule 
kinase inhibitors currently in preclinical development and in clinical use are ATP-
competitive inhibitors. These molecules are characterized by a high affinity for the kinase 
ATP-binding sites and their interaction with these sites prevents ATP binding and therefore 
kinase activation. One of the limitations of this kind of inhibitors is represented by the 
susceptibility to mutations that enhance target kinase activity, which is common in several 
types of cancer. In addition to ATP-competitive inhibitors, several non-competitive 
inhibitors have also been developed. These molecules bind to an allosteric site distant from 
the ATP-binding site and induce a conformational change of the receptor thus preventing 
the ATP binding. These kinds of inhibitors are active independently on the ATP binding site 
sequence, thus maintaining their efficacy also in the presence of mutant proteins.  
Monoclonal antibodies - An alternative approach to impair the RTKs’ activation is represented 
by the use of blocking monoclonal antibodies (mAbs) (Hinoda et al., 2004). These antibodies 
act directly preventing the ligand-receptor interaction and therefore inhibiting ligand-
mediated intracellular signaling and increasing RTK down-regulation and internalization. 
In addition, mAbs act also indirectly by stimulating the immune response. Following their 
binding to the cell surface receptors the subsequent activation of the immune system causes 
antibody-dependent cellular cytotoxicity through the activation of macrophages or natural 
killer cells. Finally, recent studies demonstrated that some monoclonal antibodies are able to 
influence tumor growth by modulating the receptor signaling activity and therefore altering 
the intracellular signaling inducing apoptosis and/or growth inhibition.  
Compared to the small molecule inhibitors, mAbs are more expensive to produce and, due 
their large molecular weight, the tissue penetration, tumor retention and blood clearance is 
less efficient especially in some tissues such as the brain. Moreover, because of their inability 
to penetrate through the cellular membrane, they can only be used to target cell surface 
molecules and not intracellular proteins. Despite these limitations, in clinical trials the mAbs 
have encountered higher approval success rates compared to new drugs, including small-
molecule agents (Reichert et al., 2005). It must be pointed out that the activation of the 
immune system is likely crucial to efficiently eliminate tumor cells and for this reason, the 
use of small molecule inhibitors in combination with mAbs should maximize the 
therapeutic effects.  
RTKs as Antiangiogenic targets - The prevention of angiogenesis is a potentially successful 
mean to impair tumor growth and progression. In contrast to standard chemotherapy, 
inhibition of angiogenesis generally does not lead to tumor regression but induces long-
term stable disease creating a favorable window of opportunity for radiotherapy or 
chemotherapy to exert stronger tumor-killing effects. Growth factors such as VEGF-A, FGF2, 
IL8 and PDGF play an important role in promoting blood vessels formation and several 
antiangiogenic molecules have been developed to target either growth factors or their 
receptors. 
The use of Bevacizumab (Avastin®), a humanized mAb able to specifically bind to VEGF-A 
and blocking its interaction with VEGFR2, in combination with 5-fluorouracil-based 
chemotherapy was approved for the first-line treatment of metastatic colorectal cancer 
(CRC) by FDA in February 2004 (Ferrara et al., 2005). Sunitinib (Sutent®) is an orally active 
small molecule inhibitor of VEGFR2, PDGFR┚, KIT and FLT3 (Mendel et al., 2003; Abrams 
et al., 2003) and is used in clinical trials for patients with advanced solid malignancies 
(Motzer et al., 2006; Motzer & Bukowski, 2006). 
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Fig. 2. Schematic representation of the therapeutic strategies targeting receptor tyrosine 
kinases; PDGFR: Platelet-derived growth factor Receptor; EGFR: Epidermal Growth Factor 
Receptor; VEGFR: Vascular Endothelial Growth Factor Receptor; FGFR: Fibroblast Growth 
Factor Receptor; KIT: c-Kit Receptor aka CD117. 
Sorafenib (Nexavar®) is a multi-kinase small molecule inhibitor able to block CRAF, BRAF, 
VEGFR2, PDGFR┚, KIT and FLT3; is used in clinical trials as monotherapy or in 
combination with standard therapy (Wilhelm et al., 2006; Liu et al., 2006). Brivanib, a dual 
tyrosine kinase inhibitor of VEGFR and FGFR signaling, was active that in phase I clinical 
trials against metastatic solid tumors refractory to standard therapy (Park et al., 2011). 
Imatinib mesilate (Gleevec®) binds to the inactive form of the BCR-ABL fusion protein 
inhibiting its activity and is used for the treatment of chronic myeloid leukemia. It also 
functions as a multi-target inhibitor of KIT and PDGFR┚. Due to this specificity it is also 
used in clinical trials for the treatment of metastatic GISTs and glioblastoma. 
Other anti-VEGF therapeutic approaches are under pre-clinical and clinical trials (Roskoski, 
Jr., 2007; Kowanetz & Ferrara, 2006). 
Anti-EGFR therapy - EGFR receptor was one of the first tyrosine kinase to be linked to tumor 
development and the dysregulation of one or more components of its pathway are a 
common trait of several tumor types. For this reason many molecules have been developed 
to try to inhibit the EGFR aberrant activity at different levels. Many of the mAbs and small 
molecules directly target the EGF receptor and some are currently used in clinical practice. 
Gefitinib (Iressa®) was the first EGFR small molecule inhibitor to enter clinical trials (Schiller, 
2003). In combination with standard therapy its activity has been evaluated in several tumor 
types such as non-small cell lung cancer and squamous cell carcinoma of the head and neck 
although no improvement in overall survival and response rate has been reported yet. 
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Cetuximab (Erbitux®), a human-mouse chimeric antibody able to bind and inhibit EGF 
receptor is used for the treatment of metastatic colorectal cancer (Goldberg, 2005). A higher 
response rate to the therapy was observed in combination with irinotecan, oxaliplatin or 
radiotherapy in different tumor types, highlighting the importance of acting on different 
cellular activities to inhibit tumor growth. 
Panitumumab (Vectibix®) is another anti-EGFR antibody (Giusti et al., 2007) that has shown 
efficacy in chemotherapy refractory colorectal cancers and is being used in clinical trials for 
the treatment of esophageal, head and neck and lung tumors. Trastuzumab (Herceptin®) is 
a mAb approved in 1998 for the treatment of HER2-positive breast cancer patients in 
combination with paclitaxel and doxorubicin. This molecule is able to bind to the 
extracellular domain of ERBB2 preventing receptor dimerization and the subsequent 
signaling cascade. 
Most of the failures with the use of some of these drugs may be due to a wrong selection of 
the patients. Indeed the utility of a personalized therapy derived from a patient selection 
based on tumor molecular profile has been demonstrated for several of these targeted 
therapeutics, including cetuximab and trastuzumab. The presence of a specific genomic 
and/or proteomic profile in fact correlates with the response to the therapy. Finally, other 
molecules that target multiple members of the EGF receptor family are currently under 
investigation (Reid et al., 2007) and some of them such as XL647 and AEE788 have shown to 
be active in vitro and are in different phases of clinical trials. 
Considering the complexity of the mechanisms regulating tumor progression, the most 
effective approach in impairing tumor development is to simultaneously target different 
pathways. The increasing knowledge about the crosstalk between cancer cells and tumor 
microenvironment will allow the development of new drugs in order to block different 
players of the signaling cascades. The goal is that with the use of therapies involving 
complementary and synergistic combinations will increase drug efficacy and reduce toxicity 
as well as the risk of development of resistance to the treatment.  
3.2 Apoptotic molecules 
The ability of tumor cells to evade apoptosis is one of the hallmarks of cancer progression 
and can play a significant role in their resistance to conventional therapeutic regimens. To 
overcome resistance to apoptosis through the development of therapeutic drugs tackling the 
single components of the pathway is one of the efforts that is being attempted to potentiate 
the anti-tumoral therapy (Reed & Pellecchia, 2005). Researchers have also focused the 
attention on different agents able to indirectly modulate apoptosis (Fig. 3). Histone 
deacetylase (HDAC) inhibitors, for example, can reduce transcription of anti-apoptotic 
molecules of the Bcl2 family and are currently under investigation in clinical trials. Small-
molecule drugs and mAbs directed against various RTKs analyzed in the previous section 
also affect this pathway and induce tumor cells to become more sensitive to apoptosis. 
Personalized treatments can be achieved given that the tumor-specific genetic lesions that 
affect sensitivity or resistance to apoptosis are well known (Zivny et al., 2010). In addition, 
different therapeutic strategies have been hypothesized or are currently under evaluation 
taking into account all the microenvironment molecules found to affect apoptosis. For 
instance, the in vitro anti-proliferative effect of exogenous SPARC could be exploited 
therapeutically by administering recombinant SPARC or one of its derivate peptides to 
patients. Pre-clinical studies are encouraging and demonstrate that subcutaneously 
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administered SPARC can inhibit the growth of neuroblastoma xenografts in mice (Chlenski 
et al., 2002). Moreover, exogenous SPARC can reverse the acquired resistance to 
chemotherapeutic agents (Tai et al., 2005). As previously explained, integrins are involved in 
anchorage independent growth, anoikis resistance and metastasis formation, which are all 
characteristics of malignant tumor cells. For this reason small molecule antagonists able to 
block the integrin binding to the ECM molecules are currently under evaluation. As an 
example RGD-mimetic peptides have been extensively used in pre-clinical studies (Eble & 
Haier, 2006). Cilengitide, a cyclic peptidic antagonist of ┙v┚3 and ┙v┚5, to block also RGD-
independent effects and to achieve a more efficacious anti-tumoral effect, for example 
(Paolillo et al., 2009). Furthermore, thanks to the capacity of the HS side chains of HSPGs to 
bind a multitude of growth factors, chemochines, cytochines and enzymes, neutralizing 
antibodies or antisense oligonucleotides have been demonstrated to enhance apoptosis in a 
number of tumor cells and may represent promising therapeutic approaches (Fukumoto et 
al., 2000). The abnormal PG expression in cancer and stromal cells may serve as a biomarker 
for tumor progression and patient survival. In this context, the better understanding of role 
of PGs in cancer progression may represent a novel approach in directly targeting the tumor 
microenvironment (Theocharis et al., 2010).  
 
 
Fig. 3. Schematic representation of the therapeutic strategies targeting apoptosis. PGs: 
Proteoglycans; ┙4┚1 and ┙v┚5: integrin receptors; CCN1, SPARC and EMILIN2: extracellular 
matrix molecules; TNF ┙: Tumor Necrosis Factor ┙; TNF-R1: Tumor Necrosis Factor Receptor 
1; Fas and TRAIL-R (TNF-Related Apoptosis Inducing Ligand Receptor) death receptors; 
FADD (Fas-Associated protein with Death Domain): adapter molecule of the extrinsic 
apoptotic pathway; ROS: Reactive Oxygen Species; FLIP: FLICE-like inhibitory protein. 
Finally, also the ECM molecule EMILIN2 may represent a good target in this context and 
increasing its levels at the tumor site may suggest a therapeutic use since EMILIN2 exerts 
pro-apoptotic effects for tumor cells enhancing the extrinsic apoptotic pathway but leaves 
normal cells unharmed. This hypothesis is well supported by pre-clinical studies (Mongiat 
et al., 2007; Mongiat et al., 2010).  
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3.3 Cells of the microenvironment 
Targeting CAFs - CAFs are the primary cells within the tumor stroma that determine the 
tumor dynamics. Despite their frequent genomic instability, they are more sensitive to 
chemotherapeutic drugs than tumor cells and thus are considered potential innovative 
therapeutic targets (Fig. 4). Many epithelial tumor cells secrete PDGF but lack PDGFR that is 
expressed by CAFs and its activation is frequently associated with metastases in colon 
carcinomas (Pietras et al., 2001; Bouzin & Feron, 2007; Haubeiss et al., 2010). In a recent 
study, the activity of four different FDA approved PDGF inhibitors such as Dasatinib, 
Imatinib, Nilotinib and Sorafenib has been compared and all were found to reduce CAFs’ 
viability. Dasatinib resulted the most efficacious and inhibited not only CAFs’ viability, but 
also induced a quiescent state and partially reverting their phenotype to normal. In 
addition, the incubation of cancer cells with conditioned media from CAFs pre-incubated 
with Dasatinib resulted in a significant reduction of tumor cell proliferation (Haubeiss et al., 
2010). PDGF inhibitors also reduced the contractility of myofibroblasts in the tumor, thereby 
reducing interstitial fluid pressure and increasing chemotherapeutic drugs uptake. 
Encouraging results in inhibiting PDGF┚-R were also obtained using CDP860, a Fab’ 
fragment-polyethylene glycol conjugate (Bouzin & Feron, 2007).  
 
 
Fig. 4. Schematic representation of the therapeutic strategies targeting tumor associated cells 
FAP: Fibroblast Activating Protein; CAF: Cancer Associated Fibroblasts; PDGFR: Platelet-
Derived Growth Factor Receptor; ┙-CSF1 and ┙-CSF1R: antibodies against the Colony 
Stimulating Factor 1 and its receptor; ┙-CXCR4: antibodies against the C-X-C chemockine 
receptor type 4; ┙-IL10R: antibodies against the Interleukin 10 Receptor ; VEGFR2: Vascular 
Endothelial Growth Factor 2; VDAs: Vascular Disrupting Agents. 
Another potential therapeutic target is the Fibroblast Activating Protein (FAP), a serine 
protease actively implicated in ECM remodeling and over-expressed in different tumors. 
Several studies underline its involvement in immunosuppression, promotion of tumor 
growth and increased metastatic potential (Bouzin & Feron, 2007; Loeffler et al., 2006; 
Kraman et al., 2010). Apart from a FAP-antibody an oral DNA vaccine against FAP is also 
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under evaluation. Through a specific CD8+ T cell-mediated killing of CAFs, this vaccine 
successfully affected both primary tumor growth and metastases of multidrug-resistant 
murine colon and breast carcinomas. Accordingly, FAP vaccinated mice display a reduction 
of intra-tumoral collagen I and thus an increased doxorubicin uptake leading in many cases 
to tumor rejection and increased lifespan (Loeffler et al., 2006). 
Targeting TAMs - Possible therapeutic strategies targeting TAMs are aimed at reducing the 
number and the function of these cells and/or increasing their antitumor activity. Different 
groups reported that TAM are committed to produce high levels of the inhibitory cytokine 
IL10, which mediates defective IL12 production and NF-kB activation in TAMs, an event 
which is very important in determining TAMs activity and that is frequently correlated with 
poor prognosis. It has been demonstrated that the employment of anti-IL10 receptor 
antibodies and Toll-like receptor 9 ligand CpG can restore NF-kB activity and revert the 
macrophages phenotype from M2 to M1 status, thus activating an innate response against 
tumor (Guiducci et al., 2005).  
Another way to reduce the number of TAMs is to target molecules that are involved in the 
recruitment of macrophages. In this perspective, the employment of antibodies against 
chemokines or chemokines receptors such as CFS1/CSF-1R could have important 
therapeutic effects.  
Given the important role of TAMs in supporting angiogenesis, antiangiogenic drugs also 
represent a therapeutic tool against TAMs. Tumor infiltrating macrophages are a significant 
source of VEGF that act as a loop by recruiting other macrophages. Thus targeting this 
growth factor could reduce the number of TAMs in the tumor stroma. Linomide is an 
interesting antiangiogenic drug that is effective in the reduction of tumor growth in a 
murine prostate cancer model. Its activity includes the inhibition of macrophages 
recruitment and the increase of antiangiogenic molecules in TAMs such as IL12, IL18, 
CXCL10 and CXCL9. Hypoxia induces HIF, and hence VEGF expression in TAMs and HIF 
could represent another interesting target. Hypoxia signaling also leads to an increase in 
CXCR4 expression both on TAMs and ECs and CXCR4 antibodies such as AMD3100 inhibit 
tumor angiogenesis in vivo (Mantovani et al., 2004; Mantovani et al., 2006).  
Anti-tumor agents with selective cytotoxic activity on monocyte-macrophages would be 
ideal therapeutic tools for their combined action on tumor cells and TAMs. Yondelis 
(Trabectedin), a natural product derived from the marine organism Ecteinascidia turbinate 
displays a potent anti-tumor activity and is specifically cytotoxic to macrophages and 
TAMs, while sparing the lymphocyte sub-set (Sessa et al., 2005). In addition, Yondelis 
inhibits the production of CCL2 and IL6 by TAMs which in turn contribute to growth 
suppression of inflammation-associated human tumors (Allavena et al., 2005). 
A legumain-based vaccine represents another strategy aimed at inducing the host to 
contrast the infiltration of TAMs in the tumor. In fact, legumain, a member of the 
endopeptidase family, is highly over-expressed by TAMs in murine and human breast 
tumor tissues, and hence provides an ideal strategy for breast tumor targeting (Lewen et al., 
2008; Xiang et al., 2008). The vaccination of mice against legumain provides a robust CD8+ T 
cell response against TAMs, significantly reducing tumor growth. Moreover, a dramatic 
reduction in TGF┚, TNF┙, MMP9 and VEGF expression is induced, with a consequent 
reduction of both angiogenesis and metastatic rate (Luo et al., 2006).  
Targeting ECs and pericytes - Besides targeting pro-angiogenetic growth factors and cytokines 
as mentioned above it is also possible to specifically target ECs and pericytes. The selective 
disruption of tumor vessels through the employment of the so called vascular disrupting 
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agents (VDAs) is a potentially useful alternative strategy. These compounds that 
predominantly affect the tumor periphery and small tumor masses have a different 
mechanism of action and tolerability profile compared with conventional antiangiogenic 
drugs and thus may provide an additional clinical benefit for a wide patient population. 
VDAs act to disrupt the established tumor vasculature in order to create an extensive 
necrosis in the tumor core. On the basis of their mechanism of action, VDAs are divided into 
2 groups. The first includes the tubulin-binding agents that selectively target tumor ECs by 
disrupting their cytoskeleton. The second VDAs group includes compounds related to 
flavone acetic acid and they act in two ways; they induce ECs apoptosis and indirectly 
increase the intra-tumoral concentrations of TNF┙ and other cytokines, as well as nitric 
oxide, leading to an inhibition of tumor flow (Boehm et al., 2010; McKeage & Baguley, 2010).  
3.4 ECM and angiogenesis 
As previously mentioned, anti-angiogenic therapy represent a promising strategy for cancer 
therapy and offers the chance to avoid resistance to chemotherapeutic treatments. J. Folkman’s 
long-standing vision of angiogenesis as a therapeutic target has been increasingly validated in 
both traditional transplant tumor models and genetically engineered mouse models of cancer 
(Szentirmai et al., 2008). Important targets in this context are ECM molecules (Fig. 5) which can 
exert both pro-angiogenic or anti-angiogenic effects (Tabruyn & Griffioen, 2007).  
 
 
Fig. 5. Schematic representation of the therapeutic strategies targeting angiogenesis hinging 
on ECM molecules; TSPs: thrombospondins; MMPs: metalloproteinases; bFGF: basic 
Fibroblast Growth Factor; HSPGs: Heparan Sulfate Proteoglycans; VEGF and VEGFR2: 
Vascular Endothelial Growth Factor and one of its receptors; MMRN2: MULTIMERIN2; 
ADAMTS: A Disintegrin And Metalloproteinase with Thrombospondin Motifs; PEDF: 
Pigment Epithelial-Derived Factor; cdk-5: cyclin dependent kinase 5. 
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Pro-angiogenic ECM proteins - Many ECM proteins surrounding the vasculature including 
collagens, laminins, and fibronectins are pro-angiogenic promoting EC survival, 
proliferation, migration and tube formation. Pro-angiogenic factors such as VEGF, bFGF and 
TGF-┚ are bound and sequestered by the ECM via the heparan-like glycosaminoglycans. 
Fibronectin, a fairly ubiquitous and abundant ECM protein that becomes assembled into 
fibrils at the cell surface, is necessary for vasculogenesis, in fact if this gene is knocked out 
mice die before birth due among others, to vascular bed defects. An alternatively-spliced 
form of fibronectin that contains an extra B domain has been found in fetal and neoplastic 
tissues but not in normal adult tissues; this isoform was found to be synthesized by the 
vascular cells in malignant astrocytoma (Castellani et al., 2002) and its expression appears to 
be a precise diagnostic marker of the highest grade of glioma or glioblastoma. Also other 
studies demonstrate that this isoform may be a good marker of angiogenesis (Santimaria et 
al., 2003) and could also be a therapeutic target. 
Osteopontin, a secreted cell attachment protein, seems to be over-expressed in association 
with increased tumor angiogenesis (Hirama et al., 2003). The proangiogenic function of 
osteopontin can be attributed to its ability to promote VEGF-directed dermal microvascular 
EC migration (Senger et al., 1996) and to increase MMP-2 levels in an RGD-dependent 
manner (Teti et al., 1998). Additionally, osteopontin-bound integrin ┙v┚3 inhibits NF-kB-
dependent EC apoptosis (Cooper et al., 2002).  
Tenascin-C is a glycoprotein composed of six subunits covalently associated by disulfide 
bonds. Different human Tenascin-C isoforms are generated by alternative splicing with 
aberrantly regulation in neoplastic tissues (Jones & Jones, 2000). It is expressed around 
angiogenic vessels in many tumors and there is evidence that it promotes and regulates 
angiogenesis in vitro and in vivo. Indeed the antibodies directed against Tenascin-C in 
glioma patients induced a significant inhibition of tumor angiogenesis. 
HSPGs are necessary for stable binding of the proangiogenic growth factor bFGF to its 
receptor (Ornitz et al., 1992) and alterations in HS glycosamminoglycan in breast carcinoma 
have been shown to result in an increase in bFGF binding and receptor complex assembly. 
Perlecan deposited along blood vessels basement membrane is thought to mediate 
structural and functional interactions with different molecules (Iozzo, 2005; Mongiat et al., 
2003a). Intact perlecan is thought to be a pro-angiogenic HSPG as: i) its expression is altered 
during embryonic vasculogenesis and in neoplasia (Tapanadechopone et al., 2001; Zhou et 
al., 2004) perlecan-null mice show severe and sometimes fatal vascular and chondrogenic 
defects (Costell et al., 1999); iii) antisense targeting of perlecan blocks tumor growth and 
angiogenesis in vivo (Sharma et al., 1998); and iv) increased perlecan expression stimulates 
angiogenesis (Jiang & Couchman, 2003). Tumor cell secreted perlecan is thought to promote 
EC sprouting and proliferation, thereby promoting angiogenesis (Jiang et al., 2004). 
Interestingly a degradation product of perlecan (endorepellin) exerts an opposite effect 
(Mongiat et al., 2003b). 
Transmembrane chondroitin sulphate proteoglycan NG2 is another protein involved in 
tumor angiogenesis and has been shown to promote EC spreading perycite function 
(Ozerdem & Stallcup, 2003). An additional proangiogenic mechanism by which NG2 
promotes angiogenesis includes its ability to bind and sequester angiostatin, thus blocking 
its antiangiogenic function (Chekenya et al., 2002). All these molecules may represent 
important tools for the development of drugs able to counteract blood vessel formation. 
Anti-angiogenic ECM proteins - Among the molecules that counteract blood vessel formation 
thrombospondin-1 (TSP-1) and thrombospondin-2 (TSP-2) are the best studied and their 
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expression in tumor tissues is often inversely correlated with angiogenesis (Adams, 2001; 
Adams & Lawler, 2004; Armstrong & Bornstein, 2003). The mechanisms by which they can 
inhibit angiogenesis include: i) the induction of EC apoptosis by the binding of TSP-1, and 
potentially TSP-2, to CD36, thereby inducing Fas ligand expression (Jimenez et al., 2000; Nor 
et al., 2000); ii) the clearance of MMP-2 following lysosomal degradation of the TSP-2/MMP-
2 complex (Armstrong et al., 2002; Rodriguez-Manzaneque et al., 2001) and iii) inhibition of 
EC proliferation (Armstrong et al., 2002). 
Another extensively studied molecule is angiostatin, the cleavage product of plasminogen, 
the only not ECM antiangiogenic protein among the molecules described above. Angiostatin 
was shown to inhibit EC proliferation and motility and to down-regulate the protein level of 
cyclin-dependent kinase 5 (cdk5), a cdk absent in quiescent EC and induced by bFGF 
(Sharma et al., 2004). Angiostatin also acts by upregulating the mRNA levels of FasL and 
reducing the level of c-Flip which activates the extrinsic apoptotic pathway.  
Other endogenous angiogenesis inhibitors include cryptic fragments from ECM molecules 
such as endostatin, a specific and potent anti-angiogenic factor generated from the 
proteolytic cleavage of collagen XVIII by matrix metalloproteinases, elastases or cathepsins 
(Kim et al., 2009). Endostatin inhibits EC proliferation and migration and causes EC G1 
arrest and apoptotic cell death (Dhanabal et al., 1999). These properties have provided clues 
for development of an anti-tumor strategy with proven therapeutic effectiveness in 
numerous models of neoplasia. 
Pigment epithelial-derived factor (PEDF) was initially identified as an antiangiogenic 
protein. Its high expression has been linked to decreased microvessel density and 
suppression of tumor growth in a number of tumors including glioma as well as prostate 
carcinoma and melanoma (Abe et al., 2004). In support of a role for PEDF in inhibiting 
angiogenesis, increased microvessel density is found in PEDF deficient mouse tissues (Doll 
et al., 2003), in addition PEDF inhibits cornea neovascularisation. The mechanism whereby 
PEDF acts to inhibit angiogenesis likely resides on its ability to bind collagen and to 
potentially interfere with the adhesion of cells to the collagen (Meyer et al., 2002) as well as 
triggering Fas up-regulation and down-regulation of the VEGF mRNA levels (Takenaka et 
al., 2005). 
MULTIMERIN2 (MMRN2), also known as EndoGlyx-1, is an ECM glycoprotein exclusively 
expressed in the blood vessel in close proximity with the endothelium. In neoplastic tissues, 
MMRN2 is consistently found to be deposited along tumor capillaries and, in certain 
tumors, in the “hot spots” of neoangiogenesis (Belien et al., 1999). This protein is 
characterized by a short cluster of charged amino acids (10 out of 27 residues) located 
between the coiled-coil region and the C1q-like domain. The basic amino acids are arranged 
in a sequence similar to that of the consensus motifs responsible for the ionic interactions 
with glucosaminoglycans, such as heparin and heparan sulfate (Hileman et al., 1998) and are 
also found in heparin binding proteins such as the von Willebrand factor (Sobel et al., 1992). 
Given its deposition in tight contact with the EC surface, we have hypothesized the 
involvement of this protein in the regulation of angiogenesis and demonstrated that 
MMRN2 functions as a homeostatic molecule for ECs preventing their sprouting to form 
new vessels (unpublished results). This strong anti-angiogenic effect is reflected in a potent 
in vivo anti-tumor activity effect following treatment with MMRN2. For these reasons we are 
confident that this molecule represents a promising tool for the development of novel 
approaches to impair angiogenesis and tumor growth. 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
251 
3.5 ECM molecules involved in invasion and metastasis. 
The targeting of ECM components and ECM-remodeling enzymes that would prevent 
changes of the stroma homeostasis promoting cancer progression has received much 
attention and is becoming an increasingly attractive therapeutic approach for preventing 
cancer progression and metastasis (Fig. 6).  
 
 
Fig. 6. Schematic representation of the therapeutic strategies targeting the metastatic 
processes. E-cdh: E-cadherin; EMT: Epithelial-Mesenchymal Transition; BM: Basement 
Membrane; WK-UT1: uPA (urokinase-type Plasminogen Activator) inhibitor; TNC: 
Tenascin-c; LOX: lysil oxidase activity; BAPN: ┚-aminoproprionitrile LOX inhibitor; Ab0023 
inhibitory monoclonal antibody specific for the LOX family member LOXL2; N-cdh: N-
cadherin; hOS: hyaluronan oligosaccharides; HA: Hyaluronan; MU: HA syntetase inhibitor 
4-methylumbelliferone; MMPs: metalloproteinases; SB-3CT: MMP-2 and -9 inhibitor; FN: 
fibronectin; FN-EDB: oncofetal form of fibronectin; TNF┙: Tumor Necrosis Factor ┙. 
ECM components - The peculiar expression of tumor-associated ECM components may offer 
the opportunity to develop new strategies for cancer treatment, either targeting their 
function associated to tumor progression or by exploiting their specific localization to 
delivery bioactive molecules to the tumors. The ECM components are highly abundant in 
tumors and are often more stable than cell surface antigens. One example of this type of 
approach is offered by tenascin-C (TNC), which exerts different effects both on tumor cells 
and also on the many cell types within the tumor, thus affecting cancer progression. The 
effects on tumor and stromal cells are exerted very early in tumorigenesis and persist during 
tumor progression. Currently, the most promising approach is to target TNC with a specific 
mAb (81C6) coupled to radioactive molecules. This strategy has been successful in patients 
with recurrent primary and metastatic brain tumors, and is currently in clinical trials (Xing 
et al., 2010). A similar approach targeting the oncofetal form of fibronectin (FN-EDB) 
containing an extra-domain, and often up-regulated in tumors was particularly successful. 
Anti-FN-EDB antibodies show specific localization to a range of tumors, including brain, 
lung and colorectal cancers. This antibody has been used as a vehicle for TNF┙ and has been 
shown to induce necrosis in tumors (Allen & Louise, 2011).  
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Cell-cell and cell-ECM interactions - Integrin-targeted therapeutics have recently been proved 
beneficial in delivering chemotherapeutics, oncolytic viruses, proapoptotic peptides and 
redionucleotides to both tumor cells and the supporting vasculature. Recent studies showed 
that delivery of targeted nanoparticles loaded with doxorubicin to integrin ┙V┚3-positive 
tumor vasculature inhibited metastases while eliminating the toxicity and patients’ weight 
loss associated with the systemic administration of this drug (Desgrosellier & Cheresh, 
2010).  
HA contributes to cancer progression in many types of carcinomas and it is up-regulated in 
tumor stroma; its activated CD44 receptor is over-expressed in solid tumors unlike the non-
tumorigenic counterparts and this characteristic may also be exploited to develop new 
therapies. The membrane receptor CD44 can internalize HA, thus, HA-carrying drugs have 
the potential to be used as targeted drugs. HA–drug conjugates are internalized via CD44, 
and the drug is released and activated mainly by intracellular enzymatic hydrolysis. Several 
preclinical studies have shown that HA chemically conjugated to cytotoxic agents improves 
the anticancer properties of the agent in vitro (Sironen et al., 2011). Manipulation of HA 
synthesis alters the tumorigenicity of malignant tumors, including breast cancer. Recently, 
the HA syntetase inhibitor 4-methylumbelliferone (MU), which has been reported to inhibit 
HA synthesis dose-dependently in several cell types, was shown to exert anti-tumor effects 
inhibiting in vitro cell proliferation, migration and invasion (Urakawa et al., 2011). MU 
suppresses intra-osseous tumor growth, suggesting its potential as a therapeutic candidate 
for established breast cancer-derived bone metastasis. Additive effects of MU in 
combination with trastuzumab for the treatment of trastuzumab-resistant breast cancers 
have also been reported both in in vitro and in vivo experiments. 
The expression of integrins by various cell types involved in tumor progression and their 
ability to crosstalk with growth factor receptors has made them appealing therapeutic 
targets. Integrin inhibitors have been extensively studied as anti-cancer agents because 
integrins play a dual function: they are involved in invasion of tumor cells out of the 
primary tumor site to the metastatic sites, but they also regulate ECs migration into the 
tumor mass during angiogenesis (Veiseh et al., 2011). Velociximab, a chimeric mAb that 
inhibits integrin ┙5┚1, has been used in clinical phase II trials for renal cell carcinoma, 
metastatic melanoma and pancreatic cancer. The rationale of using velociximab in cancer 
therapy is based on the fact that this specific integrin is expressed by endothelial cells and 
up-regulated in tumor vasculature (Jarvelainen et al., 2009). The use of etaracizumab, a 
blocking antibody for ┙V┚3 integrin, directly affects not only cancer cell growth and 
angiogenesis, but also osteoclast attachment, suggesting a possible efficacy in reducing bone 
metastasis (Desgrosellier & Cheresh, 2010). 
Another strategy is based on the development of small-molecules compounds or peptide 
mimetics in order to block the integrin signaling pathways activated by ECM remodeling. A 
successful example of this strategy is cilengitide, a cyclic RGD peptide that inhibits integrins 
┙V┚3 and ┙V┚5, that has been proven promising in lung and prostate cancer patients and for 
the treatment of glioblastoma (Allen & Louise, 2011). ATN-61 is a non-RGD-based peptide 
inhibitor of integrin ┙5┚1 blocking breast cancer growth and metastasis and, in combination 
with fluorouracil, significantly reduces liver metastasis in mouse models of colon cancer 
(Desgrosellier & Cheresh, 2010). Targeting other types of ECM receptors has also been 
attempted. For example the administration of hyaluronan oligosaccharides (hOS), which 
interfere with the CD44-hyaluronan interaction are effective inhibitors of the progression of 
several tumor types, including mammary and lung carcinoma. 
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Likewise, increasing the cadherins expression could inhibit cell invasion by strengthening 
cell-cell adhesions, thus preventing the cell from escaping the primary tumor. Indeed, 
forcing the overexpression of cadherins has been the focus of some anti-invasion therapy 
studies (Junxia et al., 2010). 
Modification enzymes – The inhibition of LOX activity reduces primary tumor growth and 
mechanotransduction in the mammary epithelium. LOX inhibition prevents the invasion of 
tumor cells in vivo and abrogates bone marrow derived cells recruitment and the 
establishment of metastasis. It also destabilizes already-formed metastases reducing their 
growth and improves patients’ survival (Cox & Erler, 2011). LOX inhibitors are currently in 
development for clinical use. For example, a small-molecule lysyl oxidase inhibitor called ┚-
aminoproprionitrile (BAPN) is available for clinical studies and it prevents the invasion of 
metastatic breast cancer and melanoma cell lines in vitro (Baker et al., 2011). More recently 
the efficacy of BAPN was outperformed by the use of an inhibitory mAb (AB0023) specific 
for LOXL2, a member of the LOX family, that was efficacious in both primary and metastatic 
xenograft models of cancer, as well as in liver and lung fibrosis models (Barry-Hamilton et 
al., 2010).  
Proteases - On the basis of the pivotal roles that MMPs play in several steps of cancer 
progression, many efforts have been spent with the aim of developing safe and effective 
agents targeting MMPs. Several generations of MMPs inhibitors have been tested in phase II 
clinical trials, including peptidomimetics, non-peptidomimetics and tetracycline derivates 
(Gialeli et al., 2011). Unfortunately so far the results have been disappointing; all the clinical 
trials involving the use of MMPs inhibitors have failed to show significant efficacy and to 
increase the rates of patients’ survival (Cox & Erler, 2011). The poor success of this approach 
largely depended on the toxicity of the compounds for normal tissues, to the conflicting 
roles of MMPs in both promoting and reducing metastatic dissemination, and to the 
functional redundancy between the family members. Nevertheless, the ongoing challenge is 
the development of a new generation of highly specific MMPs inhibitors, as for example SB-
3CT that binds to the active site of MMP-2 and -9 and re-establishes the pro-enzyme 
structure. These new compounds aim at targeting the enzymes involved in ECM remodeling 
avoiding unwanted side effects. To increase the specificity of MMPs inhibitors, the future of 
drug development comprises the use of molecules targeting specific exo-sites, specific 
binding sites outside the active domain of the metalloprotease involved in substrate 
selection (Gialeli et al., 2011). 
Finally, also the uPA system (uPAS), due its involvement in many steps of cancer 
progression, including angiogenesis, cell proliferation, invasion and growth at the 
metastatic site, represents a suitable source for the development of new anti-cancer drugs. 
Several therapeutical approaches aimed at inhibiting the uPA/uPAR functions lead to anti-
tumor effects in xenograft models, including selective inhibitors of uPA activity such as WK-
UK1, antagonist peptides, mAbs able to prevent uPA/uPAR binding and gene therapy 
techniques aimed at silencing uPA/uPAR expression. However, although promising, all 
these strategies need definitive confirmation in humans as, up to now, only few uPA 
inhibitors have been used in clinical trial (Ulisse et al., 2009). 
4. Conclusions 
The cells and molecules of the tumor microenvironment hold the potential for the 
development of innovative therapeutic approaches. Many of the molecules and approaches 
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that we have taken into account in this chapter are currently in clinical trials, while some 
have only been suggested based on preliminary results and require further investigations. 
To avoid problems of toxicity and resistance to the treatments the future of cancer therapy is 
likely to involve the use of combinatorial treatments that will include conventional 
chemotherapeutic agents at lower doses and novel molecules able to halt tumor 
development with little or no toxicity for the patient.  
5. References 
Abe, R., Shimizu, T., Yamagishi, S., Shibaki, A., Amano, S., Inagaki, Y., Watanabe, H., 
Sugawara, H., Nakamura, H., Takeuchi, M., Imaizumi, T. & Shimizu, H. (2004). 
Overexpression of pigment epithelium-derived factor decreases angiogenesis and 
inhibits the growth of human malignant melanoma cells in vivo, Am J Pathol 164, 
1225-1232 
Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K. & Cherrington, J.M. (2003). SU11248 inhibits 
KIT and platelet-derived growth factor receptor beta in preclinical models of 
human small cell lung cancer, Mol. Cancer Ther. 2, 471-478 
Adams, J.C. (2001). Thrombospondins: multifunctional regulators of cell interactions, Annu. 
Rev Cell Dev. Biol 17, 25-51 
Adams, J.C. & Lawler, J. (2004). The thrombospondins, Int. J Biochem. Cell Biol 36, 961-968 
Adderley, S.R. & Fitzgerald, D.J. (2000). Glycoprotein IIb/IIIa antagonists induce apoptosis 
in rat cardiomyocytes by caspase-3 activation, J Biol Chem. 275, 5760-5766 
Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. (2008). The Yin-Yang of tumor-
associated macrophages in neoplastic progression and immune surveillance, 
Immunol. Rev 222, 155-161 
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C.O., 
Bonardi, C., Garbi, A., Lissoni, A., de, B.F., Jimeno, J. & D'Incalci, M. (2005). Anti-
inflammatory properties of the novel antitumor agent yondelis (trabectedin): 
inhibition of macrophage differentiation and cytokine production, Cancer Res 65, 
2964-2971 
Allen, M. & Louise, J.J. (2011). Jekyll and Hyde: the role of the microenvironment on the 
progression of cancer, J Pathol 223, 162-176 
Armstrong, L.C., Bjorkblom, B., Hankenson, K.D., Siadak, A.W., Stiles, C.E. & Bornstein, P. 
(2002). Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a 
caspase-independent mechanism, Mol. Biol Cell 13, 1893-1905 
Armstrong, L.C. & Bornstein, P. (2003). Thrombospondins 1 and 2 function as inhibitors of 
angiogenesis, Matrix Biol 22, 63-71 
Augsten, M., Hagglof, C., Pena, C. & Ostman, A. (2010). A digest on the role of the tumor 
microenvironment in gastrointestinal cancers, Cancer Microenviron. 3, 167-176 
Baker, A.M., Cox, T.R., Bird, D., Lang, G., Murray, G.I., Sun, X.F., Southall, S.M., Wilson, J.R. 
& Erler, J.T. (2011). The role of lysyl oxidase in SRC-dependent proliferation and 
metastasis of colorectal cancer, J Natl. Cancer Inst. 103, 407-424 
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H.M., Oyasu, M., 
Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., Garcia, C.A., Velayo, A.C., 
Jorgensen, B., Biermann, D., Tsai, D., Green, J., Zaffryar-Eilot, S., Holzer, A., Ogg, 
S., Thai, D., Neufeld, G., Van, V.P. & Smith, V. (2010). Allosteric inhibition of lysyl 
oxidase-like-2 impedes the development of a pathologic microenvironment, Nat 
Med. 16, 1009-1017 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
255 
Belien, J.A., Somi, S., de Jong, J.S., van Diest, P.J. & Baak, J.P. (1999). Fully automated 
microvessel counting and hot spot selection by image processing of whole tumour 
sections in invasive breast cancer, J Clin Pathol 52, 184-192 
Bishop, J.R., Schuksz, M. & Esko, J.D. (2007). Heparan sulphate proteoglycans fine-tune 
mammalian physiology, Nature 446, 1030-1037 
Boehm, S., Rothermundt, C., Hess, D. & Joerger, M. (2010). Antiangiogenic drugs in 
oncology: a focus on drug safety and the elderly - a mini-review, Gerontology 56, 
303-309 
Bouzin, C. & Feron, O. (2007). Targeting tumor stroma and exploiting mature tumor 
vasculature to improve anti-cancer drug delivery, Drug Resist. Updat. 10, 109-120 
Brooks, S.A., Lomax-Browne, H.J., Carter, T.M., Kinch, C.E. & Hall, D.M. (2010). Molecular 
interactions in cancer cell metastasis, Acta Histochem. 112, 3-25 
Campbell, N.E., Kellenberger, L., Greenaway, J., Moorehead, R.A., Linnerth-Petrik, N.M. & 
Petrik, J. (2010). Extracellular matrix proteins and tumor angiogenesis, J Oncol. 
2010, 586905 
Carmeliet, P., Lampugnani, M.G., Moons, L., Breviario, F., Compernolle, V., Bono, F., 
Balconi, G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M., Zanetti, A., Angellilo, A., 
Mattot, V., Nuyens, D., Lutgens, E., Clotman, F., de Ruiter, M.C., Gittenberger-de, 
G.A., Poelmann, R., Lupu, F., Herbert, J.M., Collen, D. & Dejana, E. (1999). Targeted 
deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-
mediated endothelial survival and angiogenesis, Cell 98, 147-157 
Castellani, P., Borsi, L., Carnemolla, B., Biro, A., Dorcaratto, A., Viale, G.L., Neri, D. & Zardi, L. 
(2002). Differentiation between high- and low-grade astrocytoma using a human 
recombinant antibody to the extra domain-B of fibronectin, Am J Pathol 161, 1695-1700 
Chekenya, M., Hjelstuen, M., Enger, P.O., Thorsen, F., Jacob, A.L., Probst, B., Haraldseth, O., 
Pilkington, G., Butt, A., Levine, J.M. & Bjerkvig, R. (2002). NG2 proteoglycan 
promotes angiogenesis-dependent tumor growth in CNS by sequestering 
angiostatin, FASEB J 16, 586-588 
Chetty, C., Lakka, S.S., Bhoopathi, P., Kunigal, S., Geiss, R. & Rao, J.S. (2008). Tissue 
inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix 
metalloproteinase 2-down-regulated lung cancer, Cancer Res 68, 4736-4745 
Chlenski, A., Liu, S., Crawford, S.E., Volpert, O.V., DeVries, G.H., Evangelista, A., Yang, Q., 
Salwen, H.R., Farrer, R., Bray, J. & Cohn, S.L. (2002). SPARC is a key Schwannian-
derived inhibitor controlling neuroblastoma tumor angiogenesis, Cancer Res 62, 
7357-7363 
Chua, C.C., Rahimi, N., Forsten-Williams, K. & Nugent, M.A. (2004). Heparan sulfate 
proteoglycans function as receptors for fibroblast growth factor-2 activation of 
extracellular signal-regulated kinases 1 and 2, Circ Res 94, 316-323 
Coghlin, C. & Murray, G.I. (2010). Current and emerging concepts in tumour metastasis, J 
Pathol 222, 1-15 
Cooper, C.R., Chay, C.H. & Pienta, K.J. (2002). The role of alpha(v)beta(3) in prostate cancer 
progression, Neoplasia. 4, 191-194 
Costell, M., Gustafsson, E., Aszodi, A., Morgelin, M., Bloch, W., Hunziker, E., Addicks, K., 
Timpl, R. & Fassler, R. (1999). Perlecan maintains the integrity of cartilage and 
some basement membranes, J Cell Biol 147, 1109-1122 
Cox, T.R. & Erler, J.T. (2011). Remodeling and homeostasis of the extracellular matrix: 
implications for fibrotic diseases and cancer, Dis. Model. Mech. 4, 165-178 
www.intechopen.com
 Advances in Cancer Therapy 
 
256 
Dancey, J. & Sausville, E.A. (2003). Issues and progress with protein kinase inhibitors for 
cancer treatment, Nat Rev Drug Discov. 2, 296-313 
Deckers, M.M., van Bezooijen, R.L., van der Horst, G., Hoogendam, J., van Der, B.C., 
Papapoulos, S.E. & Lowik, C.W. (2002). Bone morphogenetic proteins stimulate 
angiogenesis through osteoblast-derived vascular endothelial growth factor A, 
Endocrinology 143, 1545-1553 
Desgrosellier, J.S. & Cheresh, D.A. (2010). Integrins in cancer: biological implications and 
therapeutic opportunities, Nat Rev Cancer 10, 9-22 
Dhanabal, M., Volk, R., Ramchandran, R., Simons, M. & Sukhatme, V.P. (1999). Cloning, 
expression, and in vitro activity of human endostatin, Biochem. Biophys. Res 
Commun. 258, 345-352 
Doliana, R., Bot, S., Bonaldo, P. & Colombatti, A. (2000). EMI, a novel cysteine-rich domain 
of EMILINs and other extracellular proteins, interacts with the gC1q domains and 
participates in multimerization, FEBS Lett. 484, 164-168 
Doll, J.A., Stellmach, V.M., Bouck, N.P., Bergh, A.R., Lee, C., Abramson, L.P., Cornwell, M.L., 
Pins, M.R., Borensztajn, J. & Crawford, S.E. (2003). Pigment epithelium-derived factor 
regulates the vasculature and mass of the prostate and pancreas, Nat Med. 9, 774-780 
Dunn, J.R., Reed, J.E., du Plessis, D.G., Shaw, E.J., Reeves, P., Gee, A.L., Warnke, P. & 
Walker, C. (2006). Expression of ADAMTS-8, a secreted protease with 
antiangiogenic properties, is downregulated in brain tumours, Br. J Cancer 94, 1186-
1193 
Eble, J.A. & Haier, J. (2006). Integrins in cancer treatment, Curr. Cancer Drug Targets. 6, 89-
105 
Elbauomy, E.S., Green, A.R., Lambros, M.B., Turner, N.C., Grainge, M.J., Powe, D., Ellis, I.O. 
& Reis-Filho, J.S. (2007). FGFR1 amplification in breast carcinomas: a chromogenic 
in situ hybridisation analysis, Breast Cancer Res 9, R23 
Erez, N., Truitt, M., Olson, P., Arron, S.T. & Hanahan, D. (2010). Cancer-Associated 
Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting 
Inflammation in an NF-kappaB-Dependent Manner, Cancer Cell 17, 135-147 
Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.T. & Giaccia, A.J. 
(2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell 
recruitment to form the premetastatic niche, Cancer Cell 15, 35-44 
Erler, J.T. & Giaccia, A.J. (2006). Lysyl oxidase mediates hypoxic control of metastasis, Cancer 
Res 66, 10238-10241 
Ferrara, N., Hillan, K.J. & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody for cancer therapy, Biochem. Biophys. Res Commun. 333, 
328-335 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications, N. Engl. J. Med. 285, 1182-
1186 
Folkman, J. (2006). Angiogenesis, Annu. Rev Med. 57, 1-18 
Folkman, J. & Klagsbrun, M. (1987). Angiogenic factors, Science 235, 442-447 
Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G.S. & Albelda, 
S.M. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: 
"N1" versus "N2" TAN, Cancer Cell 16, 183-194 
Frisch, S.M. & Screaton, R.A. (2001). Anoikis mechanisms, Curr. Opin. Cell Biol 13, 555-562 
Fukumoto, M., Takahashi, J.A., Murai, N., Ueba, T., Kono, K. & Nakatsu, S. (2000). Induction 
of apoptosis in glioma cells: an approach to control tumor growth by blocking basic 
fibroblast growth factor autocrine loop, Anticancer Res 20, 4059-4065 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
257 
Geho, D.H., Bandle, R.W., Clair, T. & Liotta, L.A. (2005). Physiological mechanisms of 
tumor-cell invasion and migration, Physiology (Bethesda. ) 20, 194-200 
Gialeli, C., Theocharis, A.D. & Karamanos, N.K. (2011). Roles of matrix metalloproteinases 
in cancer progression and their pharmacological targeting, FEBS J 278, 16-27 
Giatromanolaki, A., Sivridis, E. & Koukourakis, M.I. (2006). Angiogenesis in colorectal 
cancer: prognostic and therapeutic implications, Am J Clin Oncol. 29, 408-417 
Gilmore, A.P. (2005). Anoikis, Cell Death. Differ. 12 Suppl 2, 1473-1477 
Ginath, S., Menczer, J., Friedmann, Y., Aingorn, H., Aviv, A., Tajima, K., Dantes, A., 
Glezerman, M., Vlodavsky, I. & Amsterdam, A. (2001). Expression of heparanase, 
Mdm2, and erbB2 in ovarian cancer, Int. J Oncol. 18, 1133-1144 
Giralt, J., Navalpotro, B., Hermosilla, E., de, T., I, Espin, E., Reyes, V., Cerezo, L., de las, 
H.M., Cajal, S., Armengol, M. & Benavente, S. (2006). Prognostic significance of 
vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal 
cancer treated with preoperative radiotherapy, Oncology 71, 312-319 
Giusti, R.M., Shastri, K.A., Cohen, M.H., Keegan, P. & Pazdur, R. (2007). FDA drug approval 
summary: panitumumab (Vectibix), Oncologist. 12, 577-583 
Goldberg, R.M. (2005). Cetuximab, Nat Rev Drug Discov. Suppl, S10-S11 
Gorringe, K.L., Jacobs, S., Thompson, E.R., Sridhar, A., Qiu, W., Choong, D.Y. & Campbell, 
I.G. (2007). High-resolution single nucleotide polymorphism array analysis of 
epithelial ovarian cancer reveals numerous microdeletions and amplifications, Clin 
Cancer Res 13, 4731-4739 
Gregory, A.D. & Houghton, A.M. (2011). Tumor-Associated Neutrophils: New Targets for 
Cancer Therapy, Cancer Res 
Guiducci, C., Vicari, A.P., Sangaletti, S., Trinchieri, G. & Colombo, M.P. (2005). Redirecting 
in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor 
rejection, Cancer Res 65, 3437-3446 
Guruvayoorappan, C. (2008). Tumor versus tumor-associated macrophages: how hot is the 
link?, Integr. Cancer Ther. 7, 90-95 
Guttery, D.S., Shaw, J.A., Lloyd, K., Pringle, J.H. & Walker, R.A. (2010). Expression of 
tenascin-C and its isoforms in the breast, Cancer Metastasis Rev 29, 595-606 
Han, S., Sidell, N., Roser-Page, S. & Roman, J. (2004). Fibronectin stimulates human lung 
carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression, Int. J. 
Cancer 111, 322-331 
Haubeiss, S., Schmid, J.O., Murdter, T.E., Sonnenberg, M., Friedel, G., van der Kuip, H. & 
Aulitzky, W.E. (2010). Dasatinib reverses cancer-associated fibroblasts (CAFs) from 
primary lung carcinomas to a phenotype comparable to that of normal fibroblasts, 
Mol. Cancer 9, 168 
Hawinkels, L.J., Zuidwijk, K., Verspaget, H.W., de Jonge-Muller, E.S., van, D.W., Ferreira, 
V., Fontijn, R.D., David, G., Hommes, D.W., Lamers, C.B. & Sier, C.F. (2008). VEGF 
release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer 
angiogenesis, Eur. J Cancer 44, 1904-1913 
Hazan, R.B., Qiao, R., Keren, R., Badano, I. & Suyama, K. (2004). Cadherin switch in tumor 
progression, Ann. N. Y. Acad. Sci. 1014, 155-163 
Herbst, R.S. (2004). Review of epidermal growth factor receptor biology, Int. J Radiat. Oncol. 
Biol Phys. 59, 21-26 
Hermiston, M.L. & Gordon, J.I. (1995). In vivo analysis of cadherin function in the mouse 
intestinal epithelium: essential roles in adhesion, maintenance of differentiation, 
and regulation of programmed cell death, J Cell Biol 129, 489-506 
www.intechopen.com
 Advances in Cancer Therapy 
 
258 
Hileman, R.E., Fromm, J.R., Weiler, J.M. & Linhardt, R.J. (1998). Glycosaminoglycan-protein 
interactions: definition of consensus sites in glycosaminoglycan binding proteins, 
Bioessays 20, 156-167 
Hinoda, Y., Sasaki, S., Ishida, T. & Imai, K. (2004). Monoclonal antibodies as effective 
therapeutic agents for solid tumors, Cancer Sci. 95, 621-625 
Hirama, M., Takahashi, F., Takahashi, K., Akutagawa, S., Shimizu, K., Soma, S., Shimanuki, 
Y., Nishio, K. & Fukuchi, Y. (2003). Osteopontin overproduced by tumor cells acts 
as a potent angiogenic factor contributing to tumor growth, Cancer Lett. 198, 107-
117 
Houghton, A.M. (2010). The paradox of tumor-associated neutrophils: fueling tumor growth 
with cytotoxic substances, Cell Cycle 9, 1732-1737 
Hu, M. & Polyak, K. (2008). Microenvironmental regulation of cancer development, Curr. 
Opin. Genet. Dev. 18, 27-34 
Hubbard, S.R. & Miller, W.T. (2007). Receptor tyrosine kinases: mechanisms of activation 
and signaling, Curr. Opin. Cell Biol 19, 117-123 
Hunter, T. (1995). Protein kinases and phosphatases: the yin and yang of protein 
phosphorylation and signaling, Cell 80, 225-236 
Ikeguchi, M., Fukuda, K., Yamaguchi, K., Kondo, A., Tsujitani, S. & Kaibara, N. (2003a). 
Quantitative analysis of heparanase gene expression in esophageal squamous cell 
carcinoma, Ann. Surg. Oncol. 10, 297-304 
Ikeguchi, M., Hirooka, Y. & Kaibara, N. (2003b). Heparanase gene expression and its 
correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and 
carcinoma, Eur. J Cancer 39, 86-90 
Imai, K. & Takaoka, A. (2006). Comparing antibody and small-molecule therapies for cancer, 
Nat Rev Cancer 6, 714-727 
Iozzo, R.V. (2005). Basement membrane proteoglycans: from cellar to ceiling, Nat Rev Mol. 
Cell Biol 6, 646-656 
Iozzo, R.V. & San Antonio, J.D. (2001). Heparan sulfate proteoglycans: heavy hitters in the 
angiogenesis arena, J Clin Invest 108, 349-355 
Ishizuka, T., Tanabe, C., Sakamoto, H., Aoyagi, K., Maekawa, M., Matsukura, N., Tokunaga, 
A., Tajiri, T., Yoshida, T., Terada, M. & Sasaki, H. (2002). Gene amplification 
profiling of esophageal squamous cell carcinomas by DNA array CGH, Biochem. 
Biophys. Res Commun. 296, 152-155 
Jarvelainen, H., Sainio, A., Koulu, M., Wight, T.N. & Penttinen, R. (2009). Extracellular 
matrix molecules: potential targets in pharmacotherapy, Pharmacol. Rev 61, 198-223 
Jiang, X. & Couchman, J.R. (2003). Perlecan and tumor angiogenesis, J Histochem. Cytochem. 
51, 1393-1410 
Jiang, X., Multhaupt, H., Chan, E., Schaefer, L., Schaefer, R.M. & Couchman, J.R. (2004). 
Essential contribution of tumor-derived perlecan to epidermal tumor growth and 
angiogenesis, J Histochem. Cytochem. 52, 1575-1590 
Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L. & Bouck, N. (2000). 
Signals leading to apoptosis-dependent inhibition of neovascularization by 
thrombospondin-1, Nat. Med. 6, 41-48 
Jin, Z. & El-Deiry, W.S. (2005). Overview of cell death signaling pathways, Cancer Biol Ther. 
4, 139-163 
Jones, P.L. & Jones, F.S. (2000). Tenascin-C in development and disease: gene regulation and 
cell function, Matrix Biol 19, 581-596 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
259 
Junxia, W., Ping, G., Yuan, H., Lijun, Z., Jihong, R., Fang, L., Min, L., Xi, W., Ting, H., Ke, D. 
& Huizhong, Z. (2010). Double strand RNA-guided endogeneous E-cadherin up-
regulation induces the apoptosis and inhibits proliferation of breast carcinoma cells 
in vitro and in vivo, Cancer Sci. 101, 1790-1796 
Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour 
angiogenesis, Nat. Rev. Cancer 3, 422-433 
Kalluri, R. & Zeisberg, M. (2006). Fibroblasts in cancer, Nat. Rev. Cancer 6, 392-401 
Kim, H.S., Lim, S.J. & Park, Y.K. (2009). Anti-angiogenic factor endostatin in osteosarcoma, 
APMIS 117, 716-723 
Kowanetz, M. & Ferrara, N. (2006). Vascular endothelial growth factor signaling pathways: 
therapeutic perspective, Clin Cancer Res 12, 5018-5022 
Kraman, M., Bambrough, P.J., Arnold, J.N., Roberts, E.W., Magiera, L., Jones, J.O., Gopinathan, 
A., Tuveson, D.A. & Fearon, D.T. (2010). Suppression of antitumor immunity by 
stromal cells expressing fibroblast activation protein-alpha, Science 330, 827-830 
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J.W., Carey, L., Richardson, A. 
& Weinberg, R.A. (2004). Reconstruction of functionally normal and malignant 
human breast tissues in mice, Proc. Natl. Acad. Sci. U. S. A 101, 4966-4971 
Lee, S., Jilani, S.M., Nikolova, G.V., Carpizo, D. & Iruela-Arispe, M.L. (2005). Processing of 
VEGF-A by matrix metalloproteinases regulates bioavailability and vascular 
patterning in tumors, J Cell Biol 169, 681-691 
Lewen, S., Zhou, H., Hu, H.D., Cheng, T., Markowitz, D., Reisfeld, R.A., Xiang, R. & Luo, Y. 
(2008). A Legumain-based minigene vaccine targets the tumor stroma and suppresses 
breast cancer growth and angiogenesis, Cancer Immunol. Immunother. 57, 507-515 
Lewis, C.E. & Pollard, J.W. (2006). Distinct Role of Macrophages in Different Tumor 
Microenvironments, Cancer Res. 66, 605-612 
Li, H., Fan, X. & Houghton, J. (2007). Tumor microenvironment: the role of the tumor stroma 
in cancer, J. Cell Biochem. 101, 805-815 
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M. & 
Carter, C. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor 
angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model 
PLC/PRF/5, Cancer Res 66, 11851-11858 
Loeffler, M., Kruger, J.A., Niethammer, A.G. & Reisfeld, R.A. (2006). Targeting tumor-
associated fibroblasts improves cancer chemotherapy by increasing intratumoral 
drug uptake, J Clin Invest 116, 1955-1962 
Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S.H., Dolman, C., Markowitz, D., Wu, W., 
Liu, C., Reisfeld, R.A. & Xiang, R. (2006). Targeting tumor-associated macrophages 
as a novel strategy against breast cancer, J Clin Invest 116, 2132-2141 
Malinda, K.M., Nomizu, M., Chung, M., Delgado, M., Kuratomi, Y., Yamada, Y., Kleinman, 
H.K. & Ponce, M.L. (1999). Identification of laminin alpha1 and beta1 chain 
peptides active for endothelial cell adhesion, tube formation, and aortic sprouting, 
FASEB J 13, 53-62 
Mantovani, A., Allavena, P. & Sica, A. (2004). Tumour-associated macrophages as a 
prototypic type II polarised phagocyte population: role in tumour progression, Eur. 
J Cancer 40, 1660-1667 
Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. (2002). Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes, Trends Immunol. 23, 549-555 
www.intechopen.com
 Advances in Cancer Therapy 
 
260 
Mantovani, A., Porta, C., Rubino, L., Allavena, P. & Sica, A. (2006). Tumor-associated 
macrophages (TAMs) as new target in anticancer therapy, Drug Discovery Today: 
Therapeutic Strategies 3, 361-366 
Marastoni, S., Ligresti, G., Lorenzon, E., Colombatti, A. & Mongiat, M. (2008). Extracellular 
matrix: a matter of life and death, Connect. Tissue Res. 49, 203-206 
McKeage, M.J. & Baguley, B.C. (2010). Disrupting established tumor blood vessels: an 
emerging therapeutic strategy for cancer, Cancer 116, 1859-1871 
Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., 
Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, L.J., Carver, J., Chan, E., Moss, K.G., 
Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., 
Shirazian, S., McMahon, G. & Cherrington, J.M. (2003). In vivo antitumor activity of 
SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth 
factor and platelet-derived growth factor receptors: determination of a 
pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res 9, 327-337 
Meredith, J.E., Jr., Fazeli, B. & Schwartz, M.A. (1993). The extracellular matrix as a cell 
survival factor, Mol. Biol Cell 4, 953-961 
Meyer, C., Notari, L. & Becerra, S.P. (2002). Mapping the type I collagen-binding site on 
pigment epithelium-derived factor. Implications for its antiangiogenic activity, J 
Biol Chem. 277, 45400-45407 
Misra, S., Heldin, P., Hascall, V.C., Karamanos, N.K., Skandalis, S.S., Markwald, R.R. & 
Ghatak, S. (2011). Hyaluronan-CD44 interactions as potential targets for cancer 
therapy, FEBS J 
Mongiat, M., Fu, J., Oldershaw, R., Greenhalgh, R., Gown, A.M. & Iozzo, R.V. (2003a). 
Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a 
glycoprotein involved in bone formation and angiogenesis, J. Biol. Chem. 278, 17491-
17499 
Mongiat, M., Ligresti, G., Marastoni, S., Lorenzon, E., Doliana, R. & Colombatti, A. (2007). 
Regulation of the extrinsic apoptotic pathway by the extracellular matrix 
glycoprotein EMILIN2, Mol. Cell Biol. 27, 7176-7187 
Mongiat, M., Marastoni, S., Ligresti, G., Lorenzon, E., Schiappacassi, M., Perris, R., Frustaci, 
S. & Colombatti, A. (2010). The extracellular matrix glycoprotein elastin microfibril 
interface located protein 2: a dual role in the tumor microenvironment, Neoplasia. 
12, 294-304 
Mongiat, M., Mungiguerra, G., Bot, S., Mucignat, M.T., Giacomello, E., Doliana, R. & 
Colombatti, A. (2000). Self-assembly and supramolecular organization of EMILIN, 
J. Biol. Chem. 275, 25471-25480 
Mongiat, M., Sweeney, S.M., San Antonio, J.D., Fu, J. & Iozzo, R.V. (2003b). Endorepellin, a 
novel inhibitor of angiogenesis derived from the C terminus of perlecan, J. Biol. 
Chem. 278, 4238-4249 
Motzer, R.J. & Bukowski, R.M. (2006). Targeted therapy for metastatic renal cell carcinoma, J 
Clin Oncol. 24, 5601-5608 
Motzer, R.J., Rini, B.I., Bukowski, R.M., Curti, B.D., George, D.J., Hudes, G.R., Redman, B.G., 
Margolin, K.A., Merchan, J.R., Wilding, G., Ginsberg, M.S., Bacik, J., Kim, S.T., 
Baum, C.M. & Michaelson, M.D. (2006). Sunitinib in patients with metastatic renal 
cell carcinoma, JAMA 295, 2516-2524 
Murdoch, C., Muthana, M., Coffelt, S.B. & Lewis, C.E. (2008). The role of myeloid cells in the 
promotion of tumour angiogenesis, Nat Rev Cancer 8, 618-631 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
261 
Nor, J.E., Mitra, R.S., Sutorik, M.M., Mooney, D.J., Castle, V.P. & Polverini, P.J. (2000). 
Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by 
activating the caspase death pathway, J Vasc Res 37, 209-218 
Nozue, M., Isaka, N. & Fukao, K. (2001). Over-expression of vascular endothelial growth 
factor after preoperative radiation therapy for rectal cancer, Oncol. Rep. 8, 1247-1249 
Ogasawara, S., Yano, H., Iemura, A., Hisaka, T. & Kojiro, M. (1996). Expressions of basic 
fibroblast growth factor and its receptors and their relationship to proliferation of 
human hepatocellular carcinoma cell lines, Hepatology 24, 198-205 
Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, 
V.J., Richardson, A.L. & Weinberg, R.A. (2005). Stromal fibroblasts present in 
invasive human breast carcinomas promote tumor growth and angiogenesis 
through elevated SDF-1/CXCL12 secretion, Cell 121, 335-348 
Ornitz, D.M., Yayon, A., Flanagan, J.G., Svahn, C.M., Levi, E. & Leder, P. (1992). Heparin is 
required for cell-free binding of basic fibroblast growth factor to a soluble receptor 
and for mitogenesis in whole cells, Mol. Cell Biol 12, 240-247 
Ozerdem, U. & Stallcup, W.B. (2003). Early contribution of pericytes to angiogenic sprouting 
and tube formation, Angiogenesis. 6, 241-249 
Pang, R. & Poon, R.T. (2006). Angiogenesis and antiangiogenic therapy in hepatocellular 
carcinoma, Cancer Lett. 242, 151-167 
Paolillo, M., Russo, M.A., Serra, M., Colombo, L. & Schinelli, S. (2009). Small molecule 
integrin antagonists in cancer therapy, Mini. Rev Med. Chem. 9, 1439-1446 
Park, J.W., Finn, R.S., Kim, J.S., Karwal, M., Li, R.K., Ismail, F., Thomas, M., Harris, R., 
Baudelet, C., Walters, I. & Raoul, J.L. (2011). Phase II, Open-Label Study of Brivanib 
as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma, Clin 
Cancer Res 17, 1973-1983 
Pepper, M.S. (2001). Role of the matrix metalloproteinase and plasminogen activator-
plasmin systems in angiogenesis, Arterioscler Thromb Vasc Biol 21, 1104-1117 
Pietras, K. & Ostman, A. (2010). Hallmarks of cancer: interactions with the tumor stroma, 
Exp. Cell Res 316, 1324-1331 
Pietras, K., Ostman, A., Sjoquist, M., Buchdunger, E., Reed, R.K., Heldin, C.H. & Rubin, K. 
(2001). Inhibition of platelet-derived growth factor receptors reduces interstitial 
hypertension and increases transcapillary transport in tumors, Cancer Res 61, 2929-
2934 
Pollard, J.W. (2004). Tumour-educated macrophages promote tumour progression and 
metastasis, Nat Rev Cancer 4, 71-78 
Rasanen, K. & Vaheri, A. (2010). Activation of fibroblasts in cancer stroma, Exp. Cell Res 316, 
2713-2722 
Reed, J.C. & Pellecchia, M. (2005). Apoptosis-based therapies for hematologic malignancies, 
Blood 106, 408-418 
Reichert, J.M., Rosensweig, C.J., Faden, L.B. & Dewitz, M.C. (2005). Monoclonal antibody 
successes in the clinic, Nat Biotechnol. 23, 1073-1078 
Reid, A., Vidal, L., Shaw, H. & de, B.J. (2007). Dual inhibition of ErbB1 (EGFR/HER1) and 
ErbB2 (HER2/neu), Eur. J Cancer 43, 481-489 
Rodriguez-Manzaneque, J.C., Lane, T.F., Ortega, M.A., Hynes, R.O., Lawler, J. & Iruela-
Arispe, M.L. (2001). Thrombospondin-1 suppresses spontaneous tumor growth and 
inhibits activation of matrix metalloproteinase-9 and mobilization of vascular 
endothelial growth factor, Proc. Natl. Acad. Sci. U. S. A 98, 12485-12490 
www.intechopen.com
 Advances in Cancer Therapy 
 
262 
Roskoski, R., Jr. (2007). Vascular endothelial growth factor (VEGF) signaling in tumor 
progression, Crit Rev Oncol. Hematol. 62, 179-213 
Rothhammer, T., Bataille, F., Spruss, T., Eissner, G. & Bosserhoff, A.K. (2007). Functional 
implication of BMP4 expression on angiogenesis in malignant melanoma, Oncogene 
26, 4158-4170 
Rouet, V., Hamma-Kourbali, Y., Petit, E., Panagopoulou, P., Katsoris, P., Barritault, D., 
Caruelle, J.P. & Courty, J. (2005). A synthetic glycosaminoglycan mimetic binds 
vascular endothelial growth factor and modulates angiogenesis, J Biol Chem. 280, 
32792-32800 
Sahadevan, K., Darby, S., Leung, H.Y., Mathers, M.E., Robson, C.N. & Gnanapragasam, V.J. 
(2007). Selective over-expression of fibroblast growth factor receptors 1 and 4 in 
clinical prostate cancer, J Pathol 213, 82-90 
Santimaria, M., Moscatelli, G., Viale, G.L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., 
Borsi, L., Castellani, P., Zardi, L., Neri, D. & Riva, P. (2003). Immunoscintigraphic 
detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients 
with cancer, Clin Cancer Res 9, 571-579 
Sasisekharan, R., Shriver, Z., Venkataraman, G. & Narayanasami, U. (2002). Roles of 
heparan-sulphate glycosaminoglycans in cancer, Nat Rev Cancer 2, 521-528 
Sato, S., Kigawa, J., Minagawa, Y., Okada, M., Shimada, M., Takahashi, M., Kamazawa, S. & 
Terakawa, N. (1999). Chemosensitivity and p53-dependent apoptosis in epithelial 
ovarian carcinoma, Cancer 86, 1307-1313 
Sattler, M. & Salgia, R. (2004). Targeting c-Kit mutations: basic science to novel therapies, 
Leuk. Res 28 Suppl 1, S11-S20 
Scatena, M., Almeida, M., Chaisson, M.L., Fausto, N., Nicosia, R.F. & Giachelli, C.M. (1998). 
NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival, J Cell 
Biol 141, 1083-1093 
Schiller, J.H. (2003). New directions for ZD1839 in the treatment of solid tumors, Semin. 
Oncol. 30, 49-55 
Seidler, D.G., Goldoni, S., Agnew, C., Cardi, C., Thakur, M.L., Owens, R.T., McQuillan, D.J. 
& Iozzo, R.V. (2006). Decorin protein core inhibits in vivo cancer growth and 
metabolism by hindering epidermal growth factor receptor function and triggering 
apoptosis via caspase-3 activation, J. Biol. Chem. 281, 26408-26418 
Senger, D.R., Ledbetter, S.R., Claffey, K.P., Papadopoulos-Sergiou, A., Peruzzi, C.A. & 
Detmar, M. (1996). Stimulation of endothelial cell migration by vascular 
permeability factor/vascular endothelial growth factor through cooperative 
mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin, Am J 
Pathol 149, 293-305 
Seo, D.W., Li, H., Guedez, L., Wingfield, P.T., Diaz, T., Salloum, R., Wei, B.Y. & Stetler-
Stevenson, W.G. (2003). TIMP-2 mediated inhibition of angiogenesis: an MMP-
independent mechanism, Cell 114, 171-180 
Sessa, C., de, B.F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, 
L., Marsoni, S., Jimeno, J., D'Incalci, M., Dall'o, E. & Colombo, N. (2005). 
Trabectedin for women with ovarian carcinoma after treatment with platinum and 
taxanes fails, J Clin Oncol. 23, 1867-1874 
Sharma, B., Handler, M., Eichstetter, I., Whitelock, J.M., Nugent, M.A. & Iozzo, R.V. (1998). 
Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo, J 
Clin Invest 102, 1599-1608 
www.intechopen.com
 Therapeutical Cues from the Tumor Microenvironment 
 
263 
Sharma, M.R., Tuszynski, G.P. & Sharma, M.C. (2004). Angiostatin-induced inhibition of 
endothelial cell proliferation/apoptosis is associated with the down-regulation of 
cell cycle regulatory protein cdk5, J Cell Biochem. 91, 398-409 
Simon, R., Richter, J., Wagner, U., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, 
R., Alund, G., Knonagel, H., Rist, M., Wilber, K., Anabitarte, M., Hering, F., 
Hardmeier, T., Schonenberger, A., Flury, R., Jager, P., Fehr, J.L., Schraml, P., Moch, 
H., Mihatsch, M.J., Gasser, T. & Sauter, G. (2001). High-throughput tissue 
microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in 
urinary bladder cancer, Cancer Res 61, 4514-4519 
Sironen, R.K., Tammi, M., Tammi, R., Auvinen, P.K., Anttila, M. & Kosma, V.M. (2011). 
Hyaluronan in human malignancies, Exp. Cell Res 317, 383-391 
Sobel, M., Soler, D.F., Kermode, J.C. & Harris, R.B. (1992). Localization and characterization 
of a heparin binding domain peptide of human von Willebrand factor, J Biol Chem. 
267, 8857-8862 
Sottile, J. (2004). Regulation of angiogenesis by extracellular matrix, Biochim. Biophys. Acta 
1654, 13-22 
Steeg, P.S. (2006). Tumor metastasis: mechanistic insights and clinical challenges, Nat Med. 
12, 895-904 
Szentirmai, O., Baker, C.H., Bullain, S.S., Lin, N., Takahashi, M., Folkman, J., Mulligan, R.C. 
& Carter, B.S. (2008). Successful inhibition of intracranial human glioblastoma 
multiforme xenograft growth via systemic adenoviral delivery of soluble 
endostatin and soluble vascular endothelial growth factor receptor-2: laboratory 
investigation, J Neurosurg. 108, 979-988 
Tabruyn, S.P. & Griffioen, A.W. (2007). Molecular pathways of angiogenesis inhibition, 
Biochem. Biophys. Res Commun. 355, 1-5 
Tai, I.T., Dai, M., Owen, D.A. & Chen, L.B. (2005). Genome-wide expression analysis of 
therapy-resistant tumors reveals SPARC as a novel target for cancer therapy, J Clin 
Invest 115, 1492-1502 
Takenaka, K., Yamagishi, S., Jinnouchi, Y., Nakamura, K., Matsui, T. & Imaizumi, T. (2005). 
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of 
vascular endothelial growth factor (VEGF) expression in MG63 human 
osteosarcoma cells, Life Sci. 77, 3231-3241 
Tang, M.J. & Tai, I.T. (2007). A novel interaction between procaspase 8 and SPARC enhances 
apoptosis and potentiates chemotherapy sensitivity in colorectal cancers, J. Biol. 
Chem. 282, 34457-34467 
Tapanadechopone, P., Tumova, S., Jiang, X. & Couchman, J.R. (2001). Epidermal 
transformation leads to increased perlecan synthesis with heparin-binding-growth-
factor affinity, Biochem. J 355, 517-527 
Teti, A., Farina, A.R., Villanova, I., Tiberio, A., Tacconelli, A., Sciortino, G., Chambers, A.F., 
Gulino, A. & Mackay, A.R. (1998). Activation of MMP-2 by human GCT23 giant cell 
tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is 
RGD and cell shape change dependent, Int. J Cancer 77, 82-93 
Theocharis, A.D., Skandalis, S.S., Tzanakakis, G.N. & Karamanos, N.K. (2010). Proteoglycans 
in health and disease: novel roles for proteoglycans in malignancy and their 
pharmacological targeting, FEBS J 277, 3904-3923 
Tilghman, R.W., Cowan, C.R., Mih, J.D., Koryakina, Y., Gioeli, D., Slack-Davis, J.K., 
Blackman, B.R., Tschumperlin, D.J. & Parsons, J.T. (2010). Matrix rigidity regulates 
cancer cell growth and cellular phenotype, PLoS ONE 5, e12905 
www.intechopen.com
 Advances in Cancer Therapy 
 
264 
Todorovicc, V., Chen, C.C., Hay, N. & Lau, L.F. (2005). The matrix protein CCN1 (CYR61) 
induces apoptosis in fibroblasts, J. Cell Biol. 171, 559-568 
Trimboli, A.J., Cantemir-Stone, C.Z., Li, F., Wallace, J.A., Merchant, A., Creasap, N., 
Thompson, J.C., Caserta, E., Wang, H., Chong, J.L., Naidu, S., Wei, G., Sharma, 
S.M., Stephens, J.A., Fernandez, S.A., Gurcan, M.N., Weinstein, M.B., Barsky, S.H., 
Yee, L., Rosol, T.J., Stromberg, P.C., Robinson, M.L., Pepin, F., Hallett, M., Park, M., 
Ostrowski, M.C. & Leone, G. (2009). Pten in stromal fibroblasts suppresses 
mammary epithelial tumours, Nature 461, 1084-1091 
Ulisse, S., Baldini, E., Sorrenti, S. & D'Armiento, M. (2009). The urokinase plasminogen 
activator system: a target for anti-cancer therapy, Curr. Cancer Drug Targets. 9, 32-71 
Urakawa, H., Nishida, Y., Wasa, J., Arai, E., Zhuo, L., Kimata, K., Kozawa, E., Futamura, N. 
& Ishiguro, N. (2011). Inhibition of hyaluronan synthesis in breast cancer cells by 4-
Methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of 
bone in vivo, Int. J Cancer 
Vazquez, F., Hastings, G., Ortega, M.A., Lane, T.F., Oikemus, S., Lombardo, M. & Iruela-
Arispe, M.L. (1999). METH-1, a human ortholog of ADAMTS-1, and METH-2 are 
members of a new family of proteins with angio-inhibitory activity, J Biol Chem. 
274, 23349-23357 
Veiseh, O., Kievit, F.M., Ellenbogen, R.G. & Zhang, M. (2011). Cancer Cell Invasion: 
Treatment and Monitoring Opportunities in Nanomedicine, Adv. Drug Deliv. Rev 
Walker, A., Turnbull, J.E. & Gallagher, J.T. (1994). Specific heparan sulfate saccharides 
mediate the activity of basic fibroblast growth factor, J Biol Chem. 269, 931-935 
Wernert, N. (1997). The multiple roles of tumour stroma, Virchows Arch. 430, 433-443 
Whiteside, T.L. (2007). The role of death receptor ligands in shaping tumor 
microenvironment, Immunol. Invest 36, 25-46 
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., 
Simantov, R. & Kelley, S. (2006). Discovery and development of sorafenib: a 
multikinase inhibitor for treating cancer, Nat Rev Drug Discov. 5, 835-844 
Wilkins-Port, C.E. & Higgins, P.J. (2007). Regulation of extracellular matrix remodeling 
following transforming growth factor-beta1/epidermal growth factor-stimulated 
epithelial-mesenchymal transition in human premalignant keratinocytes, Cells 
Tissues. Organs 185, 116-122 
Xiang, R., Luo, Y., Niethammer, A.G. & Reisfeld, R.A. (2008). Oral DNA vaccines target the 
tumor vasculature and microenvironment and suppress tumor growth and 
metastasis, Immunol. Rev 222, 117-128 
Xing, F., Saidou, J. & Watabe, K. (2010). Cancer associated fibroblasts (CAFs) in tumor 
microenvironment, Front Biosci. 15, 166-179 
Zhou, Z., Wang, J., Cao, R., Morita, H., Soininen, R., Chan, K.M., Liu, B., Cao, Y. & 
Tryggvason, K. (2004). Impaired angiogenesis, delayed wound healing and 
retarded tumor growth in perlecan heparan sulfate-deficient mice, Cancer Res 64, 
4699-4702 
Zivny, J., Klener, P., Jr., Pytlik, R. & Andera, L. (2010). The role of apoptosis in cancer 
development and treatment: focusing on the development and treatment of 
hematologic malignancies, Curr. Pharm. Des 16, 11-33 
Zlobec, I., Steele, R. & Compton, C.C. (2005). VEGF as a predictive marker of rectal tumor 
response to preoperative radiotherapy, Cancer 104, 2517-2521 
Zwick, E., Bange, J. & Ullrich, A. (2002). Receptor tyrosine kinases as targets for anticancer 
drugs, Trends Mol. Med. 8, 17-23 
www.intechopen.com
Advances in Cancer Therapy
Edited by Prof. Hala Gali-Muhtasib
ISBN 978-953-307-703-1
Hard cover, 568 pages
Publisher InTech
Published online 21, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book "Advances in Cancer Therapy" is a new addition to the Intech collection of books and aims at
providing scientists and clinicians with a comprehensive overview of the state of current knowledge and latest
research findings in the area of cancer therapy. For this purpose research articles, clinical investigations and
review papers that are thought to improve the readers' understanding of cancer therapy developments and/or
to keep them up to date with the most recent advances in this field have been included in this book. With
cancer being one of the most serious diseases of our times, I am confident that this book will meet the
patients', physicians' and researchers' needs.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Stefano Marastoni, Eva Andreuzzi, Roberta Colladel, Alice Paulitti, Alessandra Silvestri, Federico Todaro,
Alfonso Colombatti and Maurizio Mongiat (2011). Therapeutical Cues from the Tumor Microenvironment,
Advances in Cancer Therapy, Prof. Hala Gali-Muhtasib (Ed.), ISBN: 978-953-307-703-1, InTech, Available
from: http://www.intechopen.com/books/advances-in-cancer-therapy/therapeutical-cues-from-the-tumor-
microenvironment
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
